Mechanism	O
of	O
interleukin-10	B-protein
inhibition	O
of	O
T-helper	O
cell	O
activation	O
by	O
superantigen	B-protein
at	O
the	O
level	O
of	O
the	O
cell	O
cycle	O
.	O

We	O
have	O
analyzed	O
the	O
effects	O
of	O
interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
on	O
the	O
entry	O
of	O
quiescent	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
into	O
the	O
cell	O
cycle	O
upon	O
stimulation	O
with	O
the	O
superantigen	B-protein
staphylococcal	B-protein
enterotoxin	I-protein
B	I-protein
(	O
SEB	B-protein
)	O
.	O

IL-10	B-protein
arrested	O
cells	O
at	O
G0/G1	O
.	O

IL-10	B-protein
treatment	O
prevented	O
the	O
downregulation	O
of	O
p27	B-protein
(	I-protein
Kip1	I-protein
)	O
,	O
an	O
inhibitory	B-protein
protein	I-protein
that	O
controls	O
progression	O
out	O
of	O
the	O
G0	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

IL-10	B-protein
also	O
prevented	O
the	O
upregulation	O
of	O
the	O
G1	B-protein
cyclins	I-protein
D2	B-protein
and	O
D3	B-protein
,	O
proteins	O
necessary	O
for	O
entry	O
and	O
progression	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Associated	O
with	O
the	O
inhibition	O
of	O
the	O
cell	O
cycle	O
,	O
IL-10	B-protein
suppressed	O
SEB	B-protein
induction	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
.	O

Addition	O
of	O
exogenous	O
IL-2	B-protein
to	O
IL-10-treated	B-cell_line
cells	I-cell_line
significantly	O
reversed	O
the	O
antiproliferative	O
effects	O
of	O
IL-10	B-protein
.	O

Moreover	O
,	O
IL-10	B-protein
effects	O
on	O
the	O
early	B-protein
G1	I-protein
proteins	I-protein
p27	B-protein
(	I-protein
Kip1	I-protein
)	I-protein
and	O
cyclin	B-protein
D2	I-protein
were	O
similarly	O
reversed	O
by	O
exogenous	O
IL-2	B-protein
.	O

Although	O
this	O
reversal	O
by	O
IL-2	B-protein
was	O
pronounced	O
,	O
it	O
was	O
not	O
complete	O
,	O
suggesting	O
that	O
IL-10	B-protein
may	O
have	O
some	O
effects	O
not	O
directly	O
related	O
to	O
the	O
suppression	O
of	O
IL-2	B-protein
production	O
.	O

Cell	O
separation	O
experiments	O
suggest	O
that	O
IL-10	B-protein
can	O
effect	O
purified	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
directly	O
,	O
providing	O
functional	O
evidence	O
for	O
the	O
presence	O
of	O
IL-10	B-protein
receptors	O
on	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

IL-10	B-protein
also	O
inhibited	O
expression	O
of	O
IL-2	B-protein
transcriptional	I-protein
regulators	I-protein
c-fos	B-protein
and	O
c-jun	B-protein
,	O
which	O
also	O
inhibit	O
other	O
cell	O
functions	O
.	O

Our	O
studies	O
show	O
that	O
the	O
mechanism	O
of	O
IL-10	B-protein
regulation	O
of	O
quiescent	O
CD4	O
(	O
+	O
)	O
T-cell	O
activation	O
is	O
mainly	O
by	O
blocking	O
induction	O
of	O
IL-2	B-protein
that	O
is	O
critical	O
to	O
downregulation	O
of	O
p27	B-protein
(	I-protein
Kip1	I-protein
)	I-protein
and	O
upregulation	O
of	O
D	B-protein
cyclins	I-protein
in	O
T-cell	O
activation	O
and	O
entry	O
into	O
the	O
cell	O
cycle	O
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Mechanism	NULL
of	NULL
Interleukin-10	NULL
Inhibition	NULL
of	NULL
T-Helper	NULL
Cell	NULL
Activation	NULL
by	NULL
Superantigen	NULL
at	NULL
the	NULL
Level	NULL
of	NULL
the	NULL
Cell	NULL
Cycle	NULL
By	NULL
George	NULL
Q.	NULL
Perrin	NULL
,	NULL
Howard	NULL
M.	NULL
Johnson	NULL
,	NULL
and	NULL
Prem	NULL
S.	NULL
Subramaniam	NULL
We	NULL
have	NULL
analyzed	NULL
the	NULL
effects	NULL
of	NULL
interleukin-10	NULL
(	NULL
IL-10	NULL
)	NULL
on	NULL
the	NULL
entry	NULL
of	NULL
quiescent	NULL
CD4+*	NULL
T	NULL
cells	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
upon	NULL
stimulation	NULL
with	NULL
the	NULL
superantigen	NULL
staphylococcal	NULL
enterotoxin	NULL
B	NULL
(	NULL
SEB	NULL
)	NULL
.	NULL

IL-10	NULL
arrested	NULL
cells	NULL
at	NULL
Gy	NULL
G4	NULL
.	NULL

IL-10	NULL
treatment	NULL
prevented	NULL
the	NULL
downregulation	NULL
of	NULL
p27	NULL
``	NULL
P	NULL
!	NULL

,	NULL
an	NULL
inhibitory	NULL
protein	NULL
that	NULL
controls	NULL
progression	NULL
out	NULL
of	NULL
the	NULL
G	NULL
,	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

IL-10	NULL
also	NULL
prevented	NULL
the	NULL
upregulation	NULL
of	NULL
the	NULL
Gq	NULL
cyclins	NULL
D2	NULL
and	NULL
D3	NULL
,	NULL
proteins	NULL
necessary	NULL
for	NULL
entry	NULL
and	NULL
progression	NULL
through	NULL
the	NULL
G	NULL
;	NULL
,	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Associated	NULL
with	NULL
the	NULL
inhibition	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
IL-10	NULL
suppressed	NULL
SEB	NULL
induction	NULL
of	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
.	NULL

Addition	NULL
of	NULL
exogenous	NULL
IL-2	NULL
to	NULL
IL-10-treated	NULL
cells	NULL
significantly	NULL
reversed	NULL
the	NULL
antiproliferative	NULL
effects	NULL
of	NULL
IL-10	NULL
.	NULL

Moreover	NULL
,	NULL
IL-10	NULL
effects	NULL
on	NULL
the	NULL
early	NULL
G	NULL
,	NULL
proteins	NULL
p27	NULL
``	NULL
P	NULL
!	NULL

and	NULL
cyclin	NULL
D2	NULL
were	NULL
similarly	NULL
reversed	NULL
by	NULL
exogenous	NULL
NTERLEUKIN-10	NULL
(	NULL
IL-10	NULL
)	NULL
is	NULL
a	NULL
multifunctional	NULL
cytokine	NULL
produced	NULL
by	NULL
B	NULL
cells	NULL
,	NULL
stimulated	NULL
macrophages	NULL
,	NULL
and	NULL
subsets	NULL
of	NULL
CD4+*	NULL
T	NULL
cells	NULL
.	NULL

It	NULL
was	NULL
originally	NULL
termed	NULL
cytokine	NULL
synthesis	NULL
inhibition	NULL
factor	NULL
due	NULL
to	NULL
its	NULL
ability	NULL
to	NULL
inhibit	NULL
production	NULL
of	NULL
some	NULL
cytokines	NULL
such	NULL
as	NULL
interferon	NULL
y	NULL
and	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
.	NULL
'	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
have	NULL
both	NULL
immunostimulatory	NULL
and	NULL
immunosuppressive	NULL
properties	NULL
,	NULL
depending	NULL
on	NULL
the	NULL
target	NULL
cell	NULL
type	NULL
.	NULL

IL-10	NULL
exerts	NULL
immunostimulatory	NULL
properties	NULL
on	NULL
B	NULL
cells	NULL
and	NULL
mast	NULL
cells	NULL
and	NULL
is	NULL
a	NULL
growth	NULL
factor	NULL
for	NULL
immature	NULL
thymocytes	NULL
.	NULL

It	NULL
exerts	NULL
immunosuppressive	NULL
effects	NULL
on	NULL
cells	NULL
of	NULL
the	NULL
monocyte/macro-phage	NULL
lineage**	NULL
and	NULL
also	NULL
on	NULL
subsets	NULL
of	NULL
activated	NULL
helper	NULL
CD4+	NULL
T	NULL
cells	NULL
,	NULL
``	NULL
``	NULL
which	NULL
are	NULL
normally	NULL
found	NULL
in	NULL
a	NULL
quiescent	NULL
or	NULL
resting	NULL
Gp	NULL
state	NULL
before	NULL
activation	NULL
.	NULL

However	NULL
,	NULL
little	NULL
is	NULL
known	NULL
of	NULL
the	NULL
molecular	NULL
effects	NULL
of	NULL
IL-10	NULL
on	NULL
the	NULL
progression	NULL
of	NULL
the	NULL
target	NULL
cells	NULL
through	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

The	NULL
IL-10	NULL
receptor	NULL
has	NULL
been	NULL
found	NULL
on	NULL
macro-phages	NULL
and	NULL
B	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
T	NULL
cells	NULL
,	NULL
including	NULL
murine	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
.	NULL
``	NULL

''	NULL
Significant	NULL
levels	NULL
of	NULL
IL-10	NULL
receptor	NULL
mRNA	NULL
has	NULL
also	NULL
been	NULL
detected	NULL
in	NULL
human	NULL
CD4*	NULL
T-cell	NULL
clones.8	NULL
The	NULL
IL-10	NULL
receptor	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
class	NULL
II	NULL
(	NULL
interferon-like	NULL
)	NULL
subgroup	NULL
of	NULL
the	NULL
cytokine	NULL
receptor	NULL
family	NULL
and	NULL
has	NULL
been	NULL
found	NULL
to	NULL
have	NULL
a	NULL
high	NULL
affinity	NULL
for	NULL
the	NULL
IL-10	NULL
molecule	NULL
.	NULL

*	NULL
``	NULL
``	NULL
In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
have	NULL
specifically	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
IL-10	NULL
on	NULL
the	NULL
molecular	NULL
events	NULL
controlling	NULL
the	NULL
cell	NULL
cycle	NULL
of	NULL
CD4+*	NULL
T	NULL
cells	NULL
in	NULL
peripheral	NULL
blood	NULL
after	NULL
superantigen	NULL
stimulation	NULL
.	NULL

In	NULL
the	NULL
entry	NULL
of	NULL
quiescent	NULL
T	NULL
cells	NULL
from	NULL
the	NULL
G	NULL
,	NULL
phase	NULL
into	NULL
the	NULL
G1	NULL
From	NULL
the	NULL
Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Cell	NULL
Science	NULL
,	NULL
University	NULL
of	NULL
Florida	NULL
,	NULL
Gainesville	NULL
,	NULL
FL	NULL
.	NULL

Submitted	NULL
March	NULL
11	NULL
,	NULL
1998	NULL
;	NULL
accepted	NULL
August	NULL
23	NULL
,	NULL
1998	NULL
.	NULL

Supported	NULL
by	NULL
National	NULL
Institues	NULL
of	NULL
Health	NULL
Grant	NULL
No	NULL
.	NULL

Al	NULL
25904-08	NULL
to	NULL
HM.J	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
George	NULL
Q.	NULL
Perrin	NULL
,	NULL
Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Cell	NULL
Science	NULL
,	NULL
Room	NULL
1019	NULL
,	NULL
Bldg	NULL
981	NULL
,	NULL
No	NULL
Name	NULL
and	NULL
Museum	NULL
Roads	NULL
,	NULL
University	NULL
of	NULL
Florida	NULL
,	NULL
Gainesville	NULL
,	NULL
FL	NULL
32611	NULL
;	NULL
e-mail	NULL
:	NULL
gperrin	NULL
@	NULL
micro.ifas.ufl.edu	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
adver-tisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-4971/99/9301-0004	NULL
$	NULL
3.00/0	NULL
208	NULL
IL-2	NULL
.	NULL

Although	NULL
this	NULL
reversal	NULL
by	NULL
IL-2	NULL
was	NULL
pronounced	NULL
,	NULL
it	NULL
was	NULL
not	NULL
complete	NULL
,	NULL
suggesting	NULL
that	NULL
IL-10	NULL
may	NULL
have	NULL
some	NULL
effects	NULL
not	NULL
directly	NULL
related	NULL
to	NULL
the	NULL
suppression	NULL
of	NULL
IL-2	NULL
production	NULL
.	NULL

Cell	NULL
separation	NULL
experiments	NULL
suggest	NULL
that	NULL
IL-10	NULL
can	NULL
effect	NULL
purified	NULL
CD4+	NULL
T	NULL
cells	NULL
directly	NULL
,	NULL
providing	NULL
functional	NULL
evidence	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
IL-10	NULL
receptors	NULL
on	NULL
CD4+*	NULL
T	NULL
cells	NULL
.	NULL

IL-10	NULL
also	NULL
inhibited	NULL
expression	NULL
of	NULL
IL-2	NULL
transcriptional	NULL
regulators	NULL
c-fos	NULL
and	NULL
c-jun	NULL
,	NULL
w	NULL
hich	NULL
also	NULL
inhibit	NULL
other	NULL
cell	NULL
functions	NULL
.	NULL

Our	NULL
studies	NULL
show	NULL
that	NULL
the	NULL
mechanism	NULL
of	NULL
IL-10	NULL
regulation	NULL
of	NULL
quiescent	NULL
CD4*	NULL
T-cell	NULL
activation	NULL
is	NULL
mainly	NULL
by	NULL
blocking	NULL
induction	NULL
of	NULL
IL-2	NULL
that	NULL
is	NULL
critical	NULL
to	NULL
downregulation	NULL
of	NULL
and	NULL
upregulation	NULL
of	NULL
D	NULL
cyclins	NULL
in	NULL
T-cell	NULL
activation	NULL
and	NULL
entry	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
two	NULL
proteins	NULL
act	NULL
as	NULL
mitogenic	NULL
sensors	NULL
.	NULL

These	NULL
are	NULL
the	NULL
cyclin-dependent	NULL
kinase	NULL
(	NULL
cdk	NULL
)	NULL
inhibitor	NULL
p27°P	NULL
!	NULL

and	NULL
the	NULL
D-type	NULL
cyclins	NULL
.	NULL
'	NULL

''	NULL
These	NULL
proteins	NULL
act	NULL
in	NULL
a	NULL
reciprocal	NULL
fashion	NULL
.	NULL

Mitogenic	NULL
stimulation	NULL
causes	NULL
the	NULL
destruction	NULL
of	NULL
the	NULL
inhibitor	NULL
p27®	NULL
'	NULL
and	NULL
the	NULL
upregulation	NULL
of	NULL
cyclins	NULL
D2	NULL
and	NULL
D3	NULL
.	NULL

Cyclin	NULL
D2	NULL
expression	NULL
occurs	NULL
early	NULL
in	NULL
the	NULL
G	NULL
;	NULL
phase	NULL
and	NULL
is	NULL
followed	NULL
later	NULL
in	NULL
G	NULL
;	NULL
by	NULL
the	NULL
expression	NULL
of	NULL
cyclin	NULL
D3	NULL
.	NULL
``	NULL

The	NULL
inhibitor	NULL
p27	NULL
``	NULL
itself	NULL
inhibits	NULL
the	NULL
kinase	NULL
activity	NULL
of	NULL
complexes	NULL
formed	NULL
between	NULL
the	NULL
D	NULL
cyclins	NULL
and	NULL
select	NULL
edks	NULL
.	NULL

These	NULL
cyclin-cdk	NULL
complexes	NULL
are	NULL
responsible	NULL
for	NULL
the	NULL
phosphorylation	NULL
of	NULL
key	NULL
substrates	NULL
required	NULL
for	NULL
continued	NULL
G	NULL
;	NULL
progression	NULL
,	NULL
an	NULL
important	NULL
one	NULL
being	NULL
the	NULL
tumor-suppressor	NULL
retinoblastoma	NULL
protein	NULL
pRB	NULL
.	NULL

!	NULL
``	NULL

In	NULL
general	NULL
,	NULL
the	NULL
expression	NULL
profiles	NULL
of	NULL
p27	NULL
``	NULL
and	NULL
the	NULL
D-type	NULL
cyclins	NULL
are	NULL
faithful	NULL
markers	NULL
of	NULL
the	NULL
activation	NULL
state	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
downregulation	NULL
of	NULL
p27	NULL
``	NULL
and	NULL
the	NULL
upregulation	NULL
of	NULL
D-type	NULL
cyclins	NULL
upon	NULL
mitogenic	NULL
stimulation	NULL
are	NULL
dependent	NULL
on	NULL
the	NULL
binding	NULL
of	NULL
IL-2	NULL
to	NULL
its	NULL
receptor	NULL
.	NULL

!	NULL

The	NULL
importance	NULL
of	NULL
p27©	NULL
``	NULL
``	NULL
is	NULL
underscored	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
immunosuppressive	NULL
drugs	NULL
such	NULL
as	NULL
rapamycin	NULL
that	NULL
prevent	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
do	NULL
so	NULL
by	NULL
preventing	NULL
the	NULL
downregulation	NULL
of	NULL
p27	NULL
``	NULL
that	NULL
occurs	NULL
upon	NULL
mitogenic	NULL
stimulation	NULL
.	NULL
``	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
have	NULL
used	NULL
the	NULL
superantigen	NULL
staphylococcal	NULL
enterotoxin	NULL
B	NULL
(	NULL
SEB	NULL
)	NULL
as	NULL
the	NULL
mitogen	NULL
.	NULL

The	NULL
superantigen	NULL
SEB	NULL
is	NULL
a	NULL
potent	NULL
T-cell-specific	NULL
mitogen	NULL
that	NULL
activates	NULL
the	NULL
T-cell	NULL
receptor	NULL
in	NULL
a	NULL
major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
class	NULL
II-restricted	NULL
manner	NULL
.	NULL

'*	NULL
Thus	NULL
,	NULL
SEB	NULL
more	NULL
closely	NULL
resembles	NULL
conventional	NULL
antigens	NULL
in	NULL
terms	NULL
of	NULL
T-cell	NULL
activation	NULL
when	NULL
compared	NULL
with	NULL
mitogens	NULL
such	NULL
as	NULL
Concanavalin	NULL
A	NULL
(	NULL
ConA	NULL
)	NULL
or	NULL
phytohemaggluti-nin	NULL
(	NULL
PHA	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
T	NULL
cells	NULL
by	NULL
mitogens	NULL
such	NULL
as	NULL
superantigens	NULL
induces	NULL
the	NULL
production	NULL
of	NULL
IL-2	NULL
.	NULL

!	NULL

5	NULL
!	NULL

°	NULL
Our	NULL
data	NULL
show	NULL
that	NULL
IL-10	NULL
exerts	NULL
its	NULL
immunosuppressive	NULL
effects	NULL
on	NULL
SEB-stimulated	NULL
CD4+*	NULL
T	NULL
cells	NULL
very	NULL
early	NULL
in	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

IL-10	NULL
prevents	NULL
the	NULL
activation	NULL
of	NULL
quiescent	NULL
CD4*	NULL
T	NULL
cells	NULL
from	NULL
the	NULL
normal	NULL
resting	NULL
Gy	NULL
state	NULL
and	NULL
their	NULL
entry	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

This	NULL
quiescent	NULL
state	NULL
is	NULL
characterized	NULL
by	NULL
high	NULL
levels	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
inhibitory	NULL
protein	NULL
p27	NULL
``	NULL
and	NULL
low	NULL
levels	NULL
of	NULL
the	NULL
early	NULL
D-type	NULL
cyclin	NULL
proteins	NULL
that	NULL
are	NULL
associated	NULL
with	NULL
progression	NULL
into	NULL
the	NULL
G	NULL
;	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

These	NULL
effects	NULL
occur	NULL
in	NULL
good	NULL
part	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
the	NULL
inhibition	NULL
of	NULL
IL-2	NULL
production	NULL
but	NULL
may	NULL
also	NULL
involve	NULL
other	NULL
mechanisms	NULL
affecting	NULL
IL-2	NULL
receptor	NULL
signaling	NULL
.	NULL

Blood	NULL
,	NULL
Vol	NULL
93	NULL
,	NULL
No	NULL
1	NULL
(	NULL
January	NULL
1	NULL
)	NULL
,	NULL
1999	NULL
:	NULL
pp	NULL
208-216	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IL-10	NULL
BLOCKS	NULL
CELL	NULL
CYCLING	NULL
IN	NULL
ACTIVATED	NULL
T	NULL
CELLS	NULL
MATERIALS	NULL
AND	NULL
METHODS	NULL
Isolation	NULL
of	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
and	NULL
cell	NULL
culture	NULL
.	NULL

-	NULL
Human	NULL
cells	NULL
were	NULL
collected	NULL
from	NULL
the	NULL
whole	NULL
blood	NULL
of	NULL
normal	NULL
healthy	NULL
volunteers	NULL
or	NULL
from	NULL
leukocyte	NULL
source	NULL
packs	NULL
(	NULL
Civitan	NULL
Regional	NULL
Blood	NULL
Center	NULL
,	NULL
Gainesville	NULL
,	NULL
FL	NULL
)	NULL
.	NULL

PBMCs	NULL
were	NULL
isolated	NULL
by	NULL
Histopaque	NULL
(	NULL
Sigma	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
density	NULL
gradient	NULL
centrifugation	NULL
'	NULL
``	NULL
and	NULL
viability	NULL
was	NULL
determined	NULL
to	NULL
be	NULL
greater	NULL
than	NULL
95	NULL
%	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

For	NULL
isolation	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
PBMCs	NULL
were	NULL
loaded	NULL
onto	NULL
CD4	NULL
T	NULL
Cellect	NULL
columns	NULL
(	NULL
Biotex	NULL
,	NULL
Edmonton	NULL
,	NULL
Alberta	NULL
,	NULL
Canada	NULL
)	NULL
as	NULL
per	NULL
the	NULL
manufacturer	NULL
's	NULL
recommendation	NULL
and	NULL
cell	NULL
purity	NULL
was	NULL
assessed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
(	NULL
vol	NULL
:	NULL
vol	NULL
)	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
FBS	NULL
)	NULL
,	NULL
200	NULL
U/mL	NULL
penicillin	NULL
,	NULL
and	NULL
200	NULL
ug	NULL
streptomycin	NULL
in	NULL
a	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
atmosphere	NULL
at	NULL
37°C	NULL
and	NULL
used	NULL
immediately	NULL
.	NULL

Proliferation	NULL
assay	NULL
.	NULL

-	NULL
The	NULL
proliferative	NULL
response	NULL
of	NULL
PBMCs	NULL
to	NULL
SEB	NULL
(	NULL
Toxin	NULL
Technology	NULL
,	NULL
Sarasota	NULL
,	NULL
FL	NULL
)	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
incorporation	NULL
of	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
into	NULL
DNA	NULL
.	NULL

Specifically	NULL
,	NULL
PBMCs	NULL
were	NULL
added	NULL
to	NULL
wells	NULL
in	NULL
a	NULL
96-well	NULL
plate	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
3	NULL
X	NULL
10°	NULL
cells/mL	NULL
and	NULL
were	NULL
treated	NULL
with	NULL
either	NULL
IL-10	NULL
(	NULL
Intergen	NULL
,	NULL
Purchase	NULL
,	NULL
NY	NULL
)	NULL
at	NULL
10	NULL
U/mL	NULL
or	NULL
media	NULL
alone	NULL
and	NULL
incubated	NULL
for	NULL
48	NULL
hours	NULL
.	NULL

Media	NULL
or	NULL
SEB	NULL
was	NULL
then	NULL
added	NULL
at	NULL
the	NULL
indicated	NULL
concentrations	NULL
and	NULL
the	NULL
cultures	NULL
were	NULL
incubated	NULL
for	NULL
another	NULL
48	NULL
hours	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
200	NULL
uL/well	NULL
.	NULL

Next	NULL
,	NULL
1	NULL
uCi	NULL
of	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
in	NULL
media	NULL
was	NULL
added	NULL
per	NULL
well	NULL
and	NULL
the	NULL
plates	NULL
were	NULL
incubated	NULL
for	NULL
8	NULL
hours	NULL
before	NULL
harvest	NULL
.	NULL

All	NULL
experiments	NULL
were	NULL
performed	NULL
in	NULL
quadruplicate	NULL
.	NULL

The	NULL
proliferative	NULL
response	NULL
of	NULL
purified	NULL
CD4*	NULL
T	NULL
cells	NULL
to	NULL
SEB	NULL
was	NULL
performed	NULL
in	NULL
a	NULL
similar	NULL
manner	NULL
,	NULL
except	NULL
that	NULL
cells	NULL
were	NULL
added	NULL
to	NULL
the	NULL
plates	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
2.5	NULL
X	NULL
10	NULL
``	NULL
cells/mL	NULL
.	NULL

This	NULL
was	NULL
necessary	NULL
to	NULL
obtain	NULL
substantial	NULL
proliferation	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
experimentation	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
only	NULL
incubated	NULL
with	NULL
IL-10	NULL
for	NULL
2	NULL
hours	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
SEB	NULL
.	NULL

Flow	NULL
cytometry	NULL
.	NULL

-	NULL
PBMCs	NULL
were	NULL
added	NULL
to	NULL
6-well	NULL
plates	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
3	NULL
X	NULL
108	NULL
cells/mL	NULL
and	NULL
treated	NULL
with	NULL
IL-10	NULL
,	NULL
SEB	NULL
,	NULL
and/or	NULL
IL-2	NULL
(	NULL
Intergen	NULL
)	NULL
at	NULL
the	NULL
indicated	NULL
concentrations	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
5	NULL
mL	NULL
.	NULL

Plates	NULL
were	NULL
incubated	NULL
for	NULL
the	NULL
time	NULL
indicated	NULL
before	NULL
harvest	NULL
for	NULL
flow	NULL
cytometry	NULL
analysis	NULL
.	NULL

At	NULL
harvest	NULL
,	NULL
cells	NULL
were	NULL
gently	NULL
mixed	NULL
and	NULL
cell	NULL
counts	NULL
were	NULL
performed	NULL
.	NULL

Cells	NULL
(	NULL
1	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
added	NULL
to	NULL
a	NULL
15-mL	NULL
tube	NULL
and	NULL
washed	NULL
twice	NULL
with	NULL
12	NULL
mL	NULL
cold	NULL
standard	NULL
azide	NULL
buffer	NULL
[	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
containing	NULL
5	NULL
%	NULL
(	NULL
vol	NULL
:	NULL
vol	NULL
)	NULL
FBS	NULL
and	NULL
0.1	NULL
%	NULL
(	NULL
wt	NULL
:	NULL
vol	NULL
)	NULL
sodium	NULL
azide	NULL
]	NULL
,	NULL
centrifuging	NULL
each	NULL
time	NULL
at	NULL
500	NULL
RPM	NULL
for	NULL
10	NULL
minutes	NULL
at	NULL
4°C	NULL
.	NULL

After	NULL
carefully	NULL
removing	NULL
the	NULL
supernatant	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
adjusted	NULL
to	NULL
1	NULL
X	NULL
10	NULL
``	NULL
cells/mL	NULL
by	NULL
resuspending	NULL
the	NULL
pellet	NULL
in	NULL
80	NULL
uL	NULL
cold	NULL
standard	NULL
azide	NULL
buffer	NULL
and	NULL
adding	NULL
20	NULL
uL	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
-labeled	NULL
anti-CD4	NULL
antibody	NULL
(	NULL
Pharmingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
incubating	NULL
on	NULL
ice	NULL
for	NULL
30	NULL
minutes	NULL
in	NULL
the	NULL
dark	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
washed	NULL
twice	NULL
as	NULL
described	NULL
before	NULL
.	NULL

For	NULL
propidium	NULL
iodide	NULL
staining	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
then	NULL
resuspended	NULL
in	NULL
1	NULL
mL	NULL
of	NULL
a	NULL
0.112	NULL
%	NULL
sodium-citrate	NULL
buffer	NULL
containing	NULL
50	NULL
ug/mL	NULL
propidium	NULL
iodide	NULL
(	NULL
Sigma	NULL
)	NULL
and	NULL
100	NULL
U/mL	NULL
RNase	NULL
A	NULL
(	NULL
Sigma	NULL
)	NULL
and	NULL
allowed	NULL
to	NULL
stain	NULL
for	NULL
up	NULL
to	NULL
1	NULL
hour	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

For	NULL
intracellular	NULL
staining	NULL
of	NULL
c-fos	NULL
and	NULL
c-jun	NULL
proteins	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
as	NULL
before	NULL
,	NULL
washed	NULL
with	NULL
cold	NULL
staining	NULL
buffer	NULL
[	NULL
PBS	NULL
containing	NULL
1	NULL
%	NULL
(	NULL
vol	NULL
:	NULL
vol	NULL
)	NULL
FBS	NULL
and	NULL
0.1	NULL
%	NULL
(	NULL
wt	NULL
:	NULL
vol	NULL
)	NULL
sodium	NULL
azide	NULL
}	NULL
,	NULL
and	NULL
stained	NULL
with	NULL
FITC-labeled	NULL
anti-CD4	NULL
antibody	NULL
in	NULL
staining	NULL
buffer	NULL
as	NULL
described	NULL
before	NULL
.	NULL

After	NULL
washing	NULL
twice	NULL
with	NULL
cold	NULL
staining	NULL
buffer	NULL
and	NULL
once	NULL
with	NULL
cold	NULL
PBS	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
fixed	NULL
with	NULL
100	NULL
uL	NULL
of	NULL
4	NULL
%	NULL
(	NULL
wt	NULL
:	NULL
vol	NULL
)	NULL
paraformaldehyde	NULL
in	NULL
PBS	NULL
for	NULL
20	NULL
minutes	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
once	NULL
with	NULL
cold	NULL
PBS	NULL
and	NULL
twice	NULL
with	NULL
cold	NULL
permeabilization	NULL
buffer	NULL
[	NULL
staining	NULL
buffer	NULL
with	NULL
0.1	NULL
%	NULL
(	NULL
wt	NULL
:	NULL
vol	NULL
)	NULL
saponin	NULL
]	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
resuspended	NULL
in	NULL
100	NULL
uL	NULL
of	NULL
permeabilization	NULL
buffer	NULL
containing	NULL
0.7	NULL
pug	NULL
of	NULL
either	NULL
c-fos	NULL
or	NULL
c-jun	NULL
specific	NULL
rabbit	NULL
antibody	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
on	NULL
ice	NULL
for	NULL
30	NULL
minutes	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
twice	NULL
with	NULL
permeabilization	NULL
buffer	NULL
and	NULL
resuspended	NULL
in	NULL
permeabilization	NULL
buffer	NULL
containing	NULL
0.7	NULL
ug	NULL
of	NULL
phycoerythrin-labeled	NULL
antirabbit	NULL
antibody	NULL
(	NULL
Sigma	NULL
)	NULL
on	NULL
ice	NULL
for	NULL
30	NULL
minutes	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
again	NULL
washed	NULL
twice	NULL
with	NULL
permeabilization	NULL
209	NULL
buffer	NULL
and	NULL
washed	NULL
once	NULL
with	NULL
staining	NULL
buffer	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
1	NULL
mL	NULL
of	NULL
staining	NULL
buffer	NULL
.	NULL

For	NULL
all	NULL
flow	NULL
cytometry	NULL
analysis	NULL
,	NULL
samples	NULL
were	NULL
filtered	NULL
through	NULL
44-um	NULL
nylon	NULL
mesh	NULL
and	NULL
data	NULL
from	NULL
30,000	NULL
events	NULL
were	NULL
acquired	NULL
with	NULL
a	NULL
FACSort	NULL
(	NULL
Becton	NULL
Dickinson	NULL
Immunocytometry	NULL
Systems	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
)	NULL
using	NULL
the	NULL
LYSIS	NULL
II	NULL
software	NULL
system	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
was	NULL
performed	NULL
using	NULL
CellFIT	NULL
software	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Immunoblotting	NULL
.	NULL

-	NULL
PBMCs	NULL
were	NULL
cultured	NULL
in	NULL
6-well	NULL
plates	NULL
and	NULL
harvested	NULL
as	NULL
described	NULL
above	NULL
.	NULL

CD4	NULL
*	NULL
T	NULL
cells	NULL
were	NULL
then	NULL
isolated	NULL
by	NULL
passing	NULL
PBMCs	NULL
over	NULL
CD4	NULL
T	NULL
Cellect	NULL
columns	NULL
(	NULL
Biotex	NULL
,	NULL
Edmonton	NULL
,	NULL
Alberta	NULL
,	NULL
Canada	NULL
)	NULL
as	NULL
per	NULL
the	NULL
manufacturer	NULL
's	NULL
recommendations	NULL
.	NULL

The	NULL
resulting	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
counted	NULL
and	NULL
stored	NULL
at	NULL
-70°C	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
at	NULL
4°C	NULL
for	NULL
20	NULL
minutes	NULL
in	NULL
ice-cold	NULL
lysis	NULL
buffer	NULL
consisting	NULL
of	NULL
50	NULL
mmol/L	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
250	NULL
mmol/L	NULL
NaCl	NULL
,	NULL
1	NULL
%	NULL
(	NULL
vol	NULL
:	NULL
vol	NULL
)	NULL
Triton	NULL
X-100	NULL
,	NULL
2	NULL
mmol/L	NULL
EDTA	NULL
,	NULL
2	NULL
mmol/L	NULL
EGTA	NULL
,	NULL
50	NULL
mmol/L	NULL
NaF	NULL
,	NULL
20	NULL
mmol/L	NULL
B-glycerophosphate	NULL
,	NULL
2	NULL
mmol/L	NULL
Na-orthovanadate	NULL
,	NULL
aprotinin	NULL
(	NULL
10	NULL
pg/mL	NULL
)	NULL
,	NULL
leupeptin	NULL
(	NULL
10	NULL
pg/mL	NULL
)	NULL
,	NULL
pepstatin	NULL
(	NULL
10	NULL
ug/mL	NULL
)	NULL
,	NULL
benzamidine	NULL
(	NULL
5	NULL
ug/mL	NULL
)	NULL
,	NULL
and	NULL
1	NULL
mmol/L	NULL
fluoride	NULL
.	NULL

Samples	NULL
were	NULL
centrifuged	NULL
at	NULL
13,000	NULL
RPM	NULL
for	NULL
10	NULL
minutes	NULL
and	NULL
a	NULL
BCA	NULL
protein	NULL
assay	NULL
(	NULL
Pierce	NULL
,	NULL
Rockford	NULL
,	NULL
IL	NULL
)	NULL
was	NULL
performed	NULL
on	NULL
the	NULL
supernatants	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
protein	NULL
from	NULL
cell	NULL
lysates	NULL
(	NULL
30	NULL
to	NULL
70	NULL
ug/lane	NULL
)	NULL
were	NULL
subjected	NULL
to	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
gel	NULL
electrophoresis	NULL
.	NULL

After	NULL
Western	NULL
transfer	NULL
,	NULL
membranes	NULL
were	NULL
probed	NULL
with	NULL
1.2	NULL
ug	NULL
of	NULL
anti-p27	NULL
P	NULL
``	NULL
,	NULL
anti-cyclin	NULL
D2	NULL
,	NULL
or	NULL
anti-cyclin	NULL
D3	NULL
antibodies	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnol-ogy	NULL
)	NULL
and	NULL
developed	NULL
using	NULL
an	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
ECL	NULL
)	NULL
detection	NULL
kit	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Densitometric	NULL
analysis	NULL
of	NULL
radiographic	NULL
film	NULL
using	NULL
IA-1000	NULL
Digital	NULL
Image	NULL
Analysis	NULL
Software	NULL
(	NULL
Alpha	NULL
Innotech	NULL
Corp	NULL
,	NULL
San	NULL
Leandro	NULL
,	NULL
CA	NULL
)	NULL
was	NULL
used	NULL
to	NULL
determine	NULL
fold	NULL
increase	NULL
or	NULL
decrease	NULL
between	NULL
band	NULL
intensities	NULL
based	NULL
on	NULL
total	NULL
pixel	NULL
value	NULL
.	NULL

IL-2	NULL
assay	NULL
.	NULL

IL-2	NULL
levels	NULL
were	NULL
determined	NULL
from	NULL
cell-free	NULL
culture	NULL
supernatants	NULL
stored	NULL
at	NULL
-70°C	NULL
using	NULL
IL-2	NULL
enzyme-linked	NULL
immunosor-bent	NULL
assay	NULL
(	NULL
ELISA	NULL
)	NULL
kits	NULL
(	NULL
Intergen	NULL
)	NULL
.	NULL

Assay	NULL
protocol	NULL
was	NULL
conducted	NULL
as	NULL
described	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

All	NULL
supernatant	NULL
samples	NULL
were	NULL
tested	NULL
in	NULL
duplicate	NULL
.	NULL

RESULTS	NULL
IL-10	NULL
blocks	NULL
SEB-induced	NULL
proliferation	NULL
in	NULL
PBMCs	NULL
.	NULL

IL-10	NULL
was	NULL
first	NULL
tested	NULL
for	NULL
its	NULL
ability	NULL
to	NULL
inhibit	NULL
superantigen-induced	NULL
proliferation	NULL
of	NULL
human	NULL
lymphocytes	NULL
.	NULL

Human	NULL
PBMCs	NULL
were	NULL
treated	NULL
with	NULL
IL-10	NULL
for	NULL
up	NULL
to	NULL
2	NULL
days	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
SEB	NULL
.	NULL

These	NULL
cultures	NULL
were	NULL
then	NULL
incubated	NULL
for	NULL
up	NULL
to	NULL
5	NULL
days	NULL
,	NULL
which	NULL
was	NULL
the	NULL
time	NULL
of	NULL
optimal	NULL
proliferation	NULL
as	NULL
reflected	NULL
by	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
.	NULL

IL-10	NULL
significantly	NULL
inhibited	NULL
SEB-induced	NULL
proliferation	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
and	NULL
an	NULL
optimal	NULL
concentration	NULL
of	NULL
10	NULL
U/mL	NULL
of	NULL
IL-10	NULL
was	NULL
determined	NULL
.	NULL

Furthermore	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
1	NULL
,	NULL
10	NULL
U/mL	NULL
of	NULL
IL-10	NULL
inhibited	NULL
PBMC	NULL
proliferation	NULL
over	NULL
a	NULL
wide	NULL
range	NULL
of	NULL
concentrations	NULL
of	NULL
SEB	NULL
.	NULL

Thus	NULL
,	NULL
IL-10	NULL
blocked	NULL
SEB-induced	NULL
PBMC	NULL
proliferation	NULL
.	NULL

IL-10	NULL
inhibits	NULL
SEB-stimulated	NULL
CD4*	NULL
T	NULL
cells	NULL
from	NULL
progressing	NULL
through	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

We	NULL
next	NULL
determined	NULL
the	NULL
stage	NULL
of	NULL
the	NULL
cell	NULL
cyele	NULL
in	NULL
which	NULL
IL-10	NULL
blocked	NULL
SEB-induced	NULL
proliferation	NULL
,	NULL
looking	NULL
specifically	NULL
at	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
which	NULL
are	NULL
one	NULL
of	NULL
the	NULL
primary	NULL
targets	NULL
of	NULL
superantigen	NULL
stimulation	NULL
.	NULL

After	NULL
stimulation	NULL
for	NULL
up	NULL
to	NULL
5	NULL
days	NULL
,	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
examined	NULL
for	NULL
cell	NULL
cycle	NULL
progression	NULL
using	NULL
FITC-labeled	NULL
anti-CD4	NULL
antibodies	NULL
and	NULL
propidium	NULL
iodide	NULL
staining	NULL
.	NULL

Preliminary	NULL
experiments	NULL
using	NULL
SEB	NULL
showed	NULL
that	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
entering	NULL
the	NULL
S	NULL
phase	NULL
between	NULL
days	NULL
4	NULL
and	NULL
5	NULL
,	NULL
although	NULL
there	NULL
was	NULL
some	NULL
variation	NULL
among	NULL
donors	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
percentage	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
phase	NULL
at	NULL
these	NULL
times	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
1	NULL
,	NULL
untreated	NULL
cells	NULL
were	NULL
all	NULL
essentially	NULL
quiescent	NULL
(	NULL
>	NULL
98	NULL
%	NULL
Gy/G	NULL
;	NULL
)	NULL
.	NULL

Treatment	NULL
with	NULL
SEB	NULL
induced	NULL
cells	NULL
to	NULL
progress	NULL
through	NULL
the	NULL
G	NULL
;	NULL
phase	NULL
and	NULL
into	NULL
the	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

PERRIN	NULL
,	NULL
JOHNSON	NULL
,	NULL
AND	NULL
SUBRAMANIAM	NULL
Fig	NULL
1	NULL
.	NULL

_	NULL
IL-10	NULL
suppression	NULL
of	NULL
SEB	NULL
stimulation	NULL
:	NULL
SEB	NULL
dose-response	NULL
.	NULL

PBMCs	NULL
were	NULL
added	NULL
to	NULL
96-well	NULL
plates	NULL
at	NULL
3	NULL
x	NULL
10°	NULL
cells/mL	NULL
along	NULL
with	NULL
IL-10	NULL
at	NULL
10	NULL
U/mL	NULL
or	NULL
media	NULL
only	NULL
.	NULL

After	NULL
2	NULL
days	NULL
of	NULL
incubation	NULL
,	NULL
media	NULL
alone	NULL
or	NULL
SEB	NULL
at	NULL
varying	NULL
concentrations	NULL
was	NULL
added	NULL
and	NULL
plates	NULL
were	NULL
further	NULL
incubated	NULL
for	NULL
another	NULL
2	NULL
days	NULL
.	NULL

Proliferation	NULL
was	NULL
measured	NULL
by	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
.	NULL

Different	NULL
PBMC	NULL
donors	NULL
are	NULL
represented	NULL
in	NULL
each	NULL
experiment	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
mean	NULL
CPM	NULL
+	NULL
SD	NULL
.	NULL

Results	NULL
were	NULL
determined	NULL
to	NULL
be	NULL
statisti-	NULL
cally	NULL
significant	NULL
by	NULL
the	NULL
Student	NULL
's	NULL
f-test	NULL
(	NULL
P	NULL
<	NULL
.002	NULL
)	NULL
.	NULL

Numbers	NULL
between	NULL
curves	NULL
indicate	NULL
the	NULL
percentage	NULL
of	NULL
210	NULL
Experiment	NULL
1	NULL
80000	NULL
-O-	NULL
_	NULL
no	NULL
IL-10	NULL
--	NULL
--	NULL
--	NULL
--	NULL
@	NULL
-	NULL
_	NULL
IL-10	NULL
(	NULL
10	NULL
U/ml	NULL
)	NULL
60000	NULL
40.2	NULL
E	NULL
40000	NULL
&	NULL
20000	NULL
0	NULL
I	NULL
U	NULL
I	NULL
U	NULL
I	NULL
I	NULL
no	NULL
SEB	NULL
10	NULL
pg/ml	NULL
100	NULL
pg/ml	NULL
1	NULL
ng/ml	NULL
10	NULL
ng/ml	NULL
100	NULL
ng/ml	NULL
SEB	NULL
Experiment	NULL
2	NULL
40000	NULL
-A-	NULL
_	NULL
no	NULL
IL-10	NULL
--	NULL
--	NULL
--	NULL
--	NULL
@	NULL
-	NULL
-	NULL
1L-10	NULL
(	NULL
10	NULL
U/ml	NULL
)	NULL
30000	NULL
e	NULL
39.8	NULL
B-	NULL
20000	NULL
W	NULL
10000	NULL
D	NULL
I	NULL
U	NULL
I	NULL
I	NULL
I	NULL
U	NULL
no	NULL
SEB	NULL
10	NULL
pg/ml	NULL
100	NULL
pg/ml	NULL
1	NULL
ng/ml	NULL
10	NULL
ng/ml	NULL
100	NULL
ng/ml	NULL
SEB	NULL
cycle	NULL
.	NULL

However	NULL
,	NULL
IL-10	NULL
blocked	NULL
SEB-induced	NULL
progression	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
through	NULL
the	NULL
G	NULL
;	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

A	NULL
similar	NULL
pattern	NULL
of	NULL
inhibition	NULL
was	NULL
observed	NULL
with	NULL
3	NULL
and	NULL
30	NULL
U/mL	NULL
of	NULL
IL-10	NULL
,	NULL
with	NULL
a	NULL
resulting	NULL
dose	NULL
response	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
Table	NULL
1	NULL
.	NULL

Flow	NULL
Cytometry	NULL
Analysis	NULL
of	NULL
the	NULL
Effect	NULL
of	NULL
IL-10	NULL
on	NULL
SEB-Stimulated	NULL
CD4+	NULL
T	NULL
Cells	NULL
Cell	NULL
Cycle	NULL
Distribution	NULL
(	NULL
%	NULL
)	NULL
*	NULL
Treatment	NULL
G	NULL
;	NULL
S	NULL
G/M	NULL
Day	NULL
4	NULL
None	NULL
>	NULL
98	NULL
<	NULL
1	NULL
<	NULL
1	NULL
SEB	NULL
only	NULL
58.80	NULL
+	NULL
0.7	NULL
37.90	NULL
+	NULL
0.3	NULL
3.25	NULL
+	NULL
0.4	NULL
IL-10	NULL
+	NULL
SEB	NULL
78.95	NULL
+	NULL
2.2	NULL
19.00	NULL
+	NULL
1.6	NULL
2.05	NULL
+	NULL
0.6	NULL
Day	NULL
5	NULL
None	NULL
>	NULL
98	NULL
<	NULL
1	NULL
<	NULL
1	NULL
SEB	NULL
only	NULL
44.10	NULL
+	NULL
1.0	NULL
47.15	NULL
+	NULL
0.9	NULL
8.70	NULL
+	NULL
0.1	NULL
IL-10	NULL
+	NULL
SEB	NULL
72.95	NULL
+	NULL
2.2	NULL
22.45	NULL
+	NULL
1.8	NULL
4.70	NULL
+	NULL
0.4	NULL
*	NULL
PBMCs	NULL
were	NULL
pretreated	NULL
for	NULL
2	NULL
days	NULL
with	NULL
IL-10	NULL
(	NULL
10	NULL
U/mL	NULL
)	NULL
.	NULL

SEB	NULL
(	NULL
100	NULL
pg/mL	NULL
)	NULL
was	NULL
then	NULL
added	NULL
to	NULL
these	NULL
cultures	NULL
and	NULL
the	NULL
incubation	NULL
was	NULL
continued	NULL
for	NULL
the	NULL
indicated	NULL
number	NULL
of	NULL
days	NULL
before	NULL
flow	NULL
cytometry	NULL
analysis	NULL
.	NULL

Data	NULL
were	NULL
gated	NULL
to	NULL
analyze	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
mean	NULL
of	NULL
duplicate	NULL
samples	NULL
+	NULL
SD	NULL
.	NULL

All	NULL
differences	NULL
between	NULL
SEB	NULL
only	NULL
and	NULL
IL-10	NULL
+	NULL
SEB	NULL
treatments	NULL
were	NULL
determined	NULL
to	NULL
be	NULL
statistically	NULL
significant	NULL
by	NULL
the	NULL
Student	NULL
's	NULL
Htest	NULL
(	NULL
P	NULL
<	NULL
.01	NULL
)	NULL
.	NULL

suppression	NULL
by	NULL
IL-10	NULL
.	NULL

IL-10	NULL
inhibits	NULL
the	NULL
early	NULL
SEB-mediated	NULL
activation	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
and	NULL
prevents	NULL
their	NULL
progression	NULL
through	NULL
the	NULL
G	NULL
;	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
and	NULL
their	NULL
subsequent	NULL
entry	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

IL-10	NULL
inhibition	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
in	NULL
CD4*	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
SEB	NULL
is	NULL
dependent	NULL
on	NULL
their	NULL
activation	NULL
state	NULL
.	NULL

-	NULL
We	NULL
then	NULL
examined	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
IL-10	NULL
on	NULL
SEB	NULL
stimulation	NULL
of	NULL
PBMCs	NULL
when	NULL
added	NULL
to	NULL
cultures	NULL
at	NULL
various	NULL
times	NULL
relative	NULL
to	NULL
superantigen	NULL
addition	NULL
.	NULL

As	NULL
seen	NULL
in	NULL
Table	NULL
3	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
IL-10	NULL
(	NULL
10	NULL
U/mL	NULL
)	NULL
2	NULL
days	NULL
before	NULL
,	NULL
1	NULL
day	NULL
before	NULL
,	NULL
or	NULL
at	NULL
the	NULL
time	NULL
of	NULL
SEB	NULL
Table	NULL
2	NULL
.	NULL

Flow	NULL
Cytometry	NULL
Analysis	NULL
of	NULL
the	NULL
Effect	NULL
of	NULL
Increasing	NULL
Concentrations	NULL
of	NULL
IL-10	NULL
on	NULL
SEB-Stimulated	NULL
CD4+	NULL
T	NULL
Cells	NULL
Cell	NULL
Cycle	NULL
Distribution	NULL
(	NULL
%	NULL
)	NULL
*	NULL
IL-10	NULL
(	NULL
U/mL	NULL
)	NULL
SEB	NULL
G	NULL
:	NULL
S	NULL
G/M	NULL
0	NULL
-	NULL
>	NULL
98	NULL
<	NULL
1	NULL
<	NULL
1	NULL
30	NULL
+	NULL
80.50	NULL
16.05	NULL
345	NULL
10	NULL
+	NULL
75.10	NULL
21.00	NULL
3.85	NULL
3	NULL
+	NULL
73.80	NULL
21.60	NULL
4.50	NULL
0	NULL
+	NULL
61.50	NULL
32.00	NULL
6.50	NULL
*PBMCs	NULL
were	NULL
pretreated	NULL
for	NULL
2	NULL
days	NULL
with	NULL
IL-10	NULL
at	NULL
the	NULL
indicated	NULL
concentrations	NULL
and	NULL
then	NULL
incubated	NULL
with	NULL
SEB	NULL
(	NULL
100	NULL
pg/mL	NULL
)	NULL
for	NULL
5.5	NULL
days	NULL
before	NULL
flow	NULL
cytometry	NULL
analysis	NULL
.	NULL

Data	NULL
were	NULL
gated	NULL
to	NULL
analyze	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IL-10	NULL
BLOCKS	NULL
CELL	NULL
CYCLING	NULL
IN	NULL
ACTIVATED	NULL
T	NULL
CELLS	NULL
Table	NULL
3	NULL
.	NULL

Flow	NULL
Cytometry	NULL
Analysis	NULL
of	NULL
the	NULL
Effect	NULL
of	NULL
IL-10	NULL
Addition	NULL
at	NULL
Various	NULL
Times	NULL
Relative	NULL
to	NULL
SEB	NULL
Incubation	NULL
on	NULL
SEB-Stimulated	NULL
CD4+	NULL
T	NULL
Cells	NULL
Cell	NULL
Cycle	NULL
Distribution	NULL
(	NULL
%	NULL
)	NULL
*	NULL
Treatment	NULL
G	NULL
:	NULL
S	NULL
Go/M	NULL
None	NULL
>	NULL
98	NULL
<	NULL
1	NULL
<	NULL
1	NULL
IL-10	NULL
added	NULL
2	NULL
days	NULL
before	NULL
SEB	NULL
84.50	NULL
11.70	NULL
3.80	NULL
IL-10	NULL
added	NULL
1	NULL
day	NULL
before	NULL
SEB	NULL
88.30	NULL
8.90	NULL
2.80	NULL
IL-10	NULL
added	NULL
same	NULL
time	NULL
as	NULL
SEB	NULL
83.50	NULL
13.00	NULL
3.50	NULL
IL-10	NULL
added	NULL
1	NULL
day	NULL
after	NULL
SEB	NULL
72.10	NULL
21.90	NULL
6.00	NULL
IL-10	NULL
added	NULL
2	NULL
days	NULL
after	NULL
SEB	NULL
70.90	NULL
22.80	NULL
6.30	NULL
IL-10	NULL
added	NULL
3	NULL
days	NULL
after	NULL
SEB	NULL
70.80	NULL
22.90	NULL
6.30	NULL
IL-10	NULL
added	NULL
4	NULL
days	NULL
after	NULL
SEB	NULL
65.80	NULL
26.80	NULL
740	NULL
SEB	NULL
only	NULL
66.15	NULL
27.10	NULL
6.75	NULL
*	NULL
PBMCs	NULL
were	NULL
treated	NULL
with	NULL
IL-10	NULL
(	NULL
10	NULL
U/mL	NULL
)	NULL
at	NULL
the	NULL
times	NULL
indicated	NULL
and	NULL
incubated	NULL
with	NULL
SEB	NULL
(	NULL
100	NULL
pg/mL	NULL
)	NULL
.	NULL

At	NULL
5.5	NULL
days	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
SEB	NULL
,	NULL
cells	NULL
were	NULL
collected	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Data	NULL
were	NULL
gated	NULL
to	NULL
analyze	NULL
CD4	NULL
#	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

addition	NULL
inhibited	NULL
cell	NULL
proliferation	NULL
in	NULL
the	NULL
GyG	NULL
:	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
to	NULL
essentially	NULL
the	NULL
same	NULL
extent	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
IL-10	NULL
at	NULL
1	NULL
to	NULL
4	NULL
days	NULL
after	NULL
SEB	NULL
resulted	NULL
in	NULL
progressively	NULL
less	NULL
inhibition	NULL
of	NULL
cell	NULL
cycling	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
IL-10	NULL
4	NULL
days	NULL
after	NULL
SEB	NULL
allowed	NULL
essentially	NULL
the	NULL
same	NULL
percentage	NULL
of	NULL
cells	NULL
to	NULL
leave	NULL
the	NULL
G	NULL
;	NULL
phase	NULL
and	NULL
enter	NULL
the	NULL
cell	NULL
cycle	NULL
as	NULL
did	NULL
cells	NULL
treated	NULL
with	NULL
SEB	NULL
and	NULL
no	NULL
IL-10	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
,	NULL
once	NULL
CD4+*	NULL
T	NULL
cells	NULL
have	NULL
been	NULL
activated	NULL
by	NULL
mitogen	NULL
and	NULL
enter	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
IL-10	NULL
has	NULL
no	NULL
further	NULL
effect	NULL
on	NULL
these	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
IL-10	NULL
blocks	NULL
the	NULL
activation	NULL
of	NULL
quiescent	NULL
CD4*	NULL
T	NULL
cells	NULL
but	NULL
not	NULL
the	NULL
subsequent	NULL
proliferation	NULL
of	NULL
these	NULL
cells	NULL
.	NULL

Fig	NULL
2	NULL
.	NULL

IL-10	NULL
inhibits	NULL
the	NULL
SEB	NULL
reduction	NULL
of	NULL
p27	NULL
``	NULL
®®	NULL
'	NULL
and	NULL
prevents	NULL
SEB-induced	NULL
upregulation	NULL
of	NULL
cyclins	NULL
D2	NULL
and	NULL
D3	NULL
in	NULL
CD4+	NULL
T	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
PBMCs	NULL
were	NULL
incubated	NULL
in	NULL
6-well	NULL
plates	NULL
at	NULL
6	NULL
x	NULL
10°	NULL
cells/mL	NULL
along	NULL
with	NULL
IL-10	NULL
at	NULL
10	NULL
U/mL	NULL
or	NULL
media	NULL
only	NULL
.	NULL

After	NULL
2	NULL
days	NULL
of	NULL
incubation	NULL
,	NULL
media	NULL
alone	NULL
or	NULL
SEB	NULL
at	NULL
100	NULL
pg/mL	NULL
was	NULL
added	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
further	NULL
incubated	NULL
until	NULL
the	NULL
indicated	NULL
harvest	NULL
day	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
and	NULL
CD4+	NULL
T	NULL
cells	NULL
were	NULL
separated	NULL
and	NULL
collected	NULL
by	NULL
negative	NULL
selection	NULL
affinity	NULL
chromatography	NULL
.	NULL

Lysates	NULL
from	NULL
these	NULL
cells	NULL
were	NULL
subjected	NULL
to	NULL
SDS-polyacryl-amide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
SDS-PAGE	NULL
)	NULL
and	NULL
Western	NULL
analysis	NULL
using	NULL
antibodies	NULL
specific	NULL
for	NULL
p27®	NULL
!	NULL

,	NULL
cyclin	NULL
D2	NULL
,	NULL
and	NULL
cyclin	NULL
D3	NULL
.	NULL

The	NULL
lower	NULL
band	NULL
in	NULL
the	NULL
cyclin	NULL
D2	NULL
doublet	NULL
represents	NULL
the	NULL
faster-migrating	NULL
activated	NULL
form	NULL
of	NULL
cyclin	NULL
D2	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Quantitation	NULL
was	NULL
performed	NULL
by	NULL
densitometric	NULL
analysis	NULL
of	NULL
bands	NULL
from	NULL
day	NULL
3.5	NULL
.	NULL

The	NULL
differences	NULL
between	NULL
SEB	NULL
treatment	NULL
and	NULL
treatment	NULL
with	NULL
IL-10	NULL
and	NULL
SEB	NULL
were	NULL
found	NULL
to	NULL
be	NULL
statistically	NULL
significant	NULL
for	NULL
all	NULL
immunoblots	NULL
(	NULL
P	NULL
<	NULL
.001	NULL
)	NULL
by	NULL
the	NULL
Student	NULL
's	NULL
t-test	NULL
.	NULL

A	NULL
IL-10	NULL
:	NULL
SEB	NULL
:	NULL
DAY	NULL
:	NULL
U	NULL
Fold	NULL
Decrease	NULL
Fold	NULL
Increase	NULL
p27Kipl	NULL
211	NULL
IL-10	NULL
prevents	NULL
the	NULL
elimination	NULL
of	NULL
the	NULL
tumor	NULL
suppressor	NULL
protein	NULL
p27*	NULL
#	NULL
in	NULL
SEB-stimulated	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
gain	NULL
insight	NULL
into	NULL
how	NULL
IL-10	NULL
blocked	NULL
superantigen-induced	NULL
activation	NULL
in	NULL
the	NULL
GyG	NULL
,	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
effects	NULL
of	NULL
IL-10	NULL
on	NULL
the	NULL
tumor	NULL
suppressor	NULL
gene	NULL
protein	NULL
p27	NULL
``	NULL
'	NULL
and	NULL
on	NULL
the	NULL
cyclins	NULL
D2	NULL
and	NULL
D3	NULL
in	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

p27	NULL
!	NULL

levels	NULL
are	NULL
high	NULL
in	NULL
quiescent	NULL
Gy	NULL
cells	NULL
and	NULL
are	NULL
rapidly	NULL
reduced	NULL
in	NULL
cells	NULL
induced	NULL
to	NULL
enter	NULL
the	NULL
cell	NULL
cycle	NULL
by	NULL
mitogens	NULL
,	NULL
'	NULL
``	NULL
whereas	NULL
cyclin	NULL
D	NULL
levels	NULL
are	NULL
low	NULL
in	NULL
quiescent	NULL
cells	NULL
and	NULL
increase	NULL
upon	NULL
mitogenic	NULL
stimula-tion	NULL
.	NULL
``	NULL

''	NULL
In	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
cyclin	NULL
D2	NULL
migrates	NULL
as	NULL
a	NULL
doublet	NULL
,	NULL
with	NULL
the	NULL
faster	NULL
migrating	NULL
species	NULL
representing	NULL
the	NULL
activated	NULL
form	NULL
.	NULL
``	NULL

''	NULL
PBMCs	NULL
were	NULL
incubated	NULL
with	NULL
IL-10	NULL
(	NULL
10	NULL
U/mL	NULL
)	NULL
for	NULL
2	NULL
days	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
SEB	NULL
.	NULL

After	NULL
incubating	NULL
for	NULL
the	NULL
specified	NULL
number	NULL
of	NULL
days	NULL
,	NULL
the	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
isolated	NULL
using	NULL
negative	NULL
selection	NULL
chromatography	NULL
columns	NULL
and	NULL
the	NULL
cell	NULL
extracts	NULL
were	NULL
subjected	NULL
to	NULL
Western	NULL
analysis	NULL
for	NULL
p27	NULL
``	NULL
and	NULL
cyclins	NULL
D2	NULL
and	NULL
D3	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
2	NULL
,	NULL
untreated	NULL
quiescent	NULL
cells	NULL
showed	NULL
high	NULL
levels	NULL
of	NULL
p27P	NULL
``	NULL
.	NULL

Treatment	NULL
with	NULL
SEB	NULL
dramatically	NULL
reduced	NULL
the	NULL
levels	NULL
of	NULL
p27	NULL
``	NULL
!	NULL

by	NULL
day	NULL
3.5	NULL
.	NULL

By	NULL
comparison	NULL
,	NULL
the	NULL
p27	NULL
``	NULL
level	NULL
remained	NULL
relatively	NULL
high	NULL
in	NULL
cultures	NULL
treated	NULL
with	NULL
IL-10	NULL
even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
SEB	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
IL-10	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
p27	NULL
``	NULL
in	NULL
SEB	NULL
-treated	NULL
cultures	NULL
supports	NULL
the	NULL
conclusion	NULL
that	NULL
IL-10	NULL
inhibits	NULL
cellular	NULL
proliferation	NULL
in	NULL
the	NULL
early	NULL
Gy/G	NULL
;	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

IL-10	NULL
inhibits	NULL
the	NULL
upregulation	NULL
of	NULL
cyclins	NULL
D2	NULL
and	NULL
D3	NULL
in	NULL
SEB-stimulated	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
cyclins	NULL
D2	NULL
and	NULL
D3	NULL
were	NULL
also	NULL
strongly	NULL
affected	NULL
by	NULL
IL-10	NULL
treatment	NULL
of	NULL
SEB-stimulated	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

Figure	NULL
2	NULL
shows	NULL
that	NULL
SEB	NULL
treatment	NULL
of	NULL
quiescent	NULL
CD4+*	NULL
T	NULL
cells	NULL
increased	NULL
the	NULL
levels	NULL
of	NULL
cyclin	NULL
D3	NULL
and	NULL
the	NULL
activated	NULL
faster	NULL
migrating	NULL
form	NULL
of	NULL
cyclin	NULL
D2	NULL
by	NULL
day	NULL
3.5	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
IL-10	NULL
prevented	NULL
the	NULL
expression	NULL
of	NULL
+o	NULL
++	NULL
to	NULL
$	NULL
o	NULL
o	NULL
1.5	NULL
2.5	NULL
3.5	NULL
1.5	NULL
2.5	NULL
3.5	NULL
1.5	NULL
2.5	NULL
3.5	NULL
#	NULL
2	NULL
un	NULL
on	NULL
oa	NULL
on	NULL
~~	NULL
#	NULL
oan	NULL
a-	NULL
»	NULL
--	NULL
p27	NULL
Kip1	NULL
-	NULL
#	NULL
-	NULL
cyclin	NULL
D2	NULL
«	NULL
gz	NULL
cyclin	NULL
D3	NULL
8	NULL
-	NULL
20	NULL
{	NULL
J	NULL
Control	NULL
6-	NULL
$	NULL
157	NULL
E	NULL
SEB	NULL
Only	NULL
F	NULL
4	NULL
-	NULL
3	NULL
10-	NULL
IL-10	NULL
+	NULL
SEB	NULL
~T	NULL
ic	NULL
]	NULL
3	NULL
_	NULL
to	NULL
5	NULL
_	NULL
JOCK	NULL
_-	NULL
,	NULL
Cyclin	NULL
D2-activated	NULL
Cyclin	NULL
D	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

212	NULL
comparable	NULL
amounts	NULL
of	NULL
both	NULL
cyclin	NULL
D3	NULL
and	NULL
the	NULL
faster	NULL
migrating	NULL
form	NULL
of	NULL
cyclin	NULL
D2	NULL
over	NULL
the	NULL
same	NULL
time	NULL
period	NULL
.	NULL

As	NULL
mentioned	NULL
earlier	NULL
,	NULL
p27	NULL
``	NULL
and	NULL
the	NULL
D-type	NULL
cyclins	NULL
behave	NULL
as	NULL
sensors	NULL
for	NULL
mitogenic	NULL
stimuli	NULL
and	NULL
play	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
the	NULL
decision	NULL
of	NULL
cells	NULL
to	NULL
become	NULL
activated	NULL
,	NULL
enter	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
and	NULL
subsequently	NULL
proliferate	NULL
.	NULL

Taken	NULL
together	NULL
with	NULL
the	NULL
effects	NULL
on	NULL
p27	NULL
``	NULL
,	NULL
these	NULL
data	NULL
demonstrate	NULL
that	NULL
IL-10	NULL
affects	NULL
CD4¢*	NULL
T	NULL
cells	NULL
very	NULL
early	NULL
in	NULL
the	NULL
cell	NULL
cycle	NULL
by	NULL
antagonizing	NULL
the	NULL
ability	NULL
of	NULL
mitogens	NULL
such	NULL
as	NULL
SEB	NULL
to	NULL
activate	NULL
these	NULL
cells	NULL
to	NULL
enter	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

IL-10	NULL
inhibits	NULL
SEB-induced	NULL
IL-2	NULL
production	NULL
.	NULL

The	NULL
potent	NULL
mitogenic	NULL
activity	NULL
of	NULL
SEB	NULL
requires	NULL
the	NULL
induction	NULL
and	NULL
autocrine	NULL
effects	NULL
of	NULL
IL-2	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

IL-2	NULL
is	NULL
the	NULL
primary	NULL
cytokine	NULL
secreted	NULL
by	NULL
CD4*	NULL
T	NULL
cells	NULL
that	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
competent	NULL
T	NULL
cells	NULL
and	NULL
their	NULL
subsequent	NULL
progression	NULL
through	NULL
the	NULL
G	NULL
;	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

IL-10	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
to	NULL
block	NULL
induction	NULL
of	NULL
IL-2	NULL
.	NULL
``	NULL

Thus	NULL
,	NULL
we	NULL
next	NULL
examined	NULL
the	NULL
role	NULL
of	NULL
IL-2	NULL
in	NULL
this	NULL
system	NULL
and	NULL
its	NULL
effects	NULL
on	NULL
the	NULL
cell	NULL
cycle	NULL
events	NULL
affected	NULL
by	NULL
IL-10	NULL
.	NULL

As	NULL
seen	NULL
in	NULL
Table	NULL
4	NULL
,	NULL
treatment	NULL
with	NULL
IL-10	NULL
dramatically	NULL
inhibited	NULL
the	NULL
amount	NULL
of	NULL
IL-2	NULL
produced	NULL
during	NULL
the	NULL
time	NULL
period	NULL
of	NULL
SEB	NULL
stimulation	NULL
.	NULL

These	NULL
data	NULL
represent	NULL
IL-2	NULL
levels	NULL
in	NULL
supernatants	NULL
taken	NULL
from	NULL
the	NULL
same	NULL
cell	NULL
cultures	NULL
analyzed	NULL
in	NULL
Fig	NULL
2	NULL
.	NULL

The	NULL
changes	NULL
in	NULL
IL-2	NULL
levels	NULL
are	NULL
seen	NULL
to	NULL
precede	NULL
changes	NULL
in	NULL
the	NULL
cell	NULL
cycle	NULL
proteins	NULL
.	NULL

We	NULL
then	NULL
measured	NULL
the	NULL
amount	NULL
of	NULL
IL-2	NULL
produced	NULL
during	NULL
the	NULL
first	NULL
24	NULL
hours	NULL
after	NULL
SEB	NULL
stimulation	NULL
(	NULL
Table	NULL
5	NULL
)	NULL
to	NULL
study	NULL
the	NULL
effect	NULL
IL-10	NULL
has	NULL
on	NULL
IL-2	NULL
production	NULL
during	NULL
the	NULL
time	NULL
of	NULL
initial	NULL
T-cell	NULL
activation	NULL
.	NULL

IL-2	NULL
production	NULL
was	NULL
induced	NULL
as	NULL
early	NULL
as	NULL
12	NULL
hours	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
SEB	NULL
,	NULL
and	NULL
IL-10-treated	NULL
cells	NULL
showed	NULL
significantly	NULL
less	NULL
IL-2	NULL
production	NULL
than	NULL
did	NULL
cells	NULL
incubated	NULL
with	NULL
SEB	NULL
only	NULL
.	NULL

In	NULL
both	NULL
cases	NULL
,	NULL
similar	NULL
values	NULL
were	NULL
obtained	NULL
when	NULL
IL-10	NULL
was	NULL
added	NULL
2	NULL
days	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
SEB	NULL
and	NULL
when	NULL
IL-10	NULL
and	NULL
SEB	NULL
were	NULL
added	NULL
simultaneously	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
IL-10	NULL
blocks	NULL
induction	NULL
of	NULL
IL-2	NULL
in	NULL
the	NULL
SEB-stimulated	NULL
cultures	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
IL-2	NULL
reverses	NULL
IL-10	NULL
's	NULL
effects	NULL
on	NULL
cell	NULL
cycle	NULL
progression	NULL
in	NULL
SEB-stimulated	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

-	NULL
Next	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
addition	NULL
of	NULL
IL-2	NULL
on	NULL
the	NULL
IL-10-induced	NULL
suppression	NULL
of	NULL
SEB	NULL
stimulation	NULL
.	NULL

IL-2	NULL
at	NULL
varying	NULL
concentrations	NULL
was	NULL
added	NULL
to	NULL
PBMCs	NULL
along	NULL
with	NULL
IL-10	NULL
and	NULL
SEB	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
Table	NULL
4	NULL
.	NULL

IL-10	NULL
Effects	NULL
on	NULL
IL-2	NULL
Production	NULL
by	NULL
SEB-Stimulated	NULL
PBMCs	NULL
I2	NULL
``	NULL
Fold	NULL
Days	NULL
IL-10	NULL
SEB	NULL
pg/mL	NULL
U/mLt	NULL
Decrease	NULL
1.5	NULL
-	NULL
-	NULL
12	NULL
+	NULL
5.0	NULL
0.12	NULL
+	NULL
0.050	NULL
2.5	NULL
-	NULL
-	NULL
<	NULL
Bf	NULL
<	NULL
0.08¢	NULL
3.5	NULL
-	NULL
-	NULL
<	NULL
B	NULL
<	NULL
0.08	NULL
1.5	NULL
-	NULL
+	NULL
1,872	NULL
+	NULL
185.0	NULL
18.72	NULL
+	NULL
1.850	NULL
2.5	NULL
-	NULL
+	NULL
2,118	NULL
+	NULL
246.0	NULL
21.18	NULL
+	NULL
2.460	NULL
3.5	NULL
-	NULL
+	NULL
2,277	NULL
+	NULL
318.0	NULL
22.77	NULL
+	NULL
3.180	NULL
1.5	NULL
+	NULL
+	NULL
129	NULL
+	NULL
6.0	NULL
1.29	NULL
+	NULL
0.060	NULL
14.5	NULL
2.5	NULL
+	NULL
+	NULL
240	NULL
+	NULL
29.0	NULL
2.40	NULL
+	NULL
0.290	NULL
8.8	NULL
3.5	NULL
+	NULL
+	NULL
49	NULL
+	NULL
7.0	NULL
0.49	NULL
+	NULL
0.070	NULL
46.2	NULL
*	NULL
IL-2	NULL
was	NULL
measured	NULL
from	NULL
supernatants	NULL
from	NULL
PBMC	NULL
cultures	NULL
treated	NULL
with	NULL
media	NULL
only	NULL
,	NULL
SEB	NULL
(	NULL
100	NULL
pg/mL	NULL
)	NULL
only	NULL
,	NULL
or	NULL
IL-10	NULL
(	NULL
10	NULL
U/mL	NULL
)	NULL
for	NULL
2	NULL
days	NULL
before	NULL
SEB	NULL
(	NULL
100	NULL
pg/mL	NULL
)	NULL
.	NULL

Cell	NULL
supernatants	NULL
were	NULL
then	NULL
collected	NULL
after	NULL
the	NULL
indicated	NULL
incubation	NULL
period	NULL
.	NULL

Results	NULL
were	NULL
show	NULL
n	NULL
to	NULL
be	NULL
statistically	NULL
significant	NULL
by	NULL
the	NULL
Student	NULL
's	NULL
t-test	NULL
(	NULL
P	NULL
<	NULL
.02	NULL
)	NULL
.	NULL

{	NULL
IL-2	NULL
was	NULL
measured	NULL
in	NULL
picograms	NULL
per	NULL
milliliter	NULL
.	NULL

The	NULL
specific	NULL
activity	NULL
of	NULL
the	NULL
IL-2	NULL
standard	NULL
was	NULL
1	NULL
x	NULL
10	NULL
``	NULL
U/mg	NULL
and	NULL
was	NULL
used	NULL
to	NULL
calculate	NULL
units	NULL
per	NULL
milliliter	NULL
.	NULL

{	NULL
These	NULL
results	NULL
were	NULL
below	NULL
the	NULL
detection	NULL
limit	NULL
of	NULL
the	NULL
assay	NULL
.	NULL

PERRIN	NULL
,	NULL
JOHNSON	NULL
,	NULL
AND	NULL
SUBRAMANIAM	NULL
Table	NULL
5	NULL
.	NULL

Early	NULL
IL-10	NULL
Effects	NULL
on	NULL
IL-2	NULL
Production	NULL
by	NULL
SEB-Stimulated	NULL
PBMCs	NULL
I2	NULL
``	NULL
Fold	NULL
Hours	NULL
IL-10	NULL
SEB	NULL
pg/mL	NULL
U/mLt	NULL
Decrease	NULL
6	NULL
-	NULL
-	NULL
<	NULL
Bf	NULL
<	NULL
0.08¢	NULL
12	NULL
-	NULL
-	NULL
<	NULL
8	NULL
<	NULL
0.08	NULL
18	NULL
-	NULL
-	NULL
<	NULL
8	NULL
<	NULL
0.08	NULL
24	NULL
-	NULL
-	NULL
<	NULL
8	NULL
<	NULL
0.08	NULL
6	NULL
-	NULL
+	NULL
<	NULL
8	NULL
<	NULL
0.08	NULL
12	NULL
-	NULL
+	NULL
172	NULL
+	NULL
30.8	NULL
1.72	NULL
+	NULL
0.308	NULL
18	NULL
-	NULL
+	NULL
816	NULL
+	NULL
17.0	NULL
8.16	NULL
+	NULL
0.170	NULL
24	NULL
-	NULL
+	NULL
1,375	NULL
+	NULL
18.6	NULL
13.75	NULL
+	NULL
0.186	NULL
6	NULL
+	NULL
+	NULL
<	NULL
8	NULL
<	NULL
0.08	NULL
0	NULL
12	NULL
+	NULL
+	NULL
53	NULL
+	NULL
6.0	NULL
0.53	NULL
+	NULL
0.060	NULL
3.2	NULL
18	NULL
+	NULL
+	NULL
53	NULL
+	NULL
4.7	NULL
0.53	NULL
+	NULL
0.047	NULL
15.4	NULL
24	NULL
+	NULL
+	NULL
96	NULL
+	NULL
12.9	NULL
0.96	NULL
+	NULL
0.129	NULL
14.3	NULL
*	NULL
IL-2	NULL
was	NULL
measured	NULL
from	NULL
supernatants	NULL
from	NULL
PBMC	NULL
cultures	NULL
treated	NULL
with	NULL
media	NULL
only	NULL
,	NULL
SEB	NULL
(	NULL
100	NULL
pg/mL	NULL
)	NULL
only	NULL
,	NULL
or	NULL
IL-10	NULL
(	NULL
10	NULL
U/mL	NULL
)	NULL
for	NULL
2	NULL
days	NULL
before	NULL
SEB	NULL
(	NULL
100	NULL
pg/mL	NULL
)	NULL
.	NULL

Cell	NULL
supernatants	NULL
were	NULL
then	NULL
collected	NULL
after	NULL
the	NULL
indicated	NULL
incubation	NULL
period	NULL
.	NULL

Results	NULL
were	NULL
determined	NULL
to	NULL
be	NULL
statistically	NULL
significant	NULL
by	NULL
the	NULL
Student	NULL
's	NULL
Htest	NULL
(	NULL
P	NULL
<	NULL
.05	NULL
)	NULL
.	NULL

{	NULL
IL-2	NULL
was	NULL
measured	NULL
in	NULL
picograms	NULL
per	NULL
milliliter	NULL
.	NULL

The	NULL
specific	NULL
activity	NULL
of	NULL
the	NULL
IL-2	NULL
standard	NULL
was	NULL
1	NULL
X	NULL
10	NULL
``	NULL
U/mg	NULL
and	NULL
was	NULL
used	NULL
to	NULL
calculate	NULL
units	NULL
per	NULL
milliliter	NULL
.	NULL

{	NULL
These	NULL
results	NULL
were	NULL
below	NULL
the	NULL
detection	NULL
limit	NULL
of	NULL
the	NULL
assay	NULL
.	NULL

then	NULL
incubated	NULL
for	NULL
5	NULL
days	NULL
and	NULL
the	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
examined	NULL
for	NULL
cell	NULL
cycle	NULL
progression	NULL
using	NULL
FITC-labeled	NULL
anti-CD4	NULL
antibodies	NULL
and	NULL
propidium	NULL
iodide	NULL
staining	NULL
.	NULL

Table	NULL
6	NULL
shows	NULL
that	NULL
the	NULL
addition	NULL
of	NULL
IL-2	NULL
overcame	NULL
the	NULL
suppressive	NULL
effect	NULL
of	NULL
IL-10	NULL
in	NULL
these	NULL
cells	NULL
and	NULL
allowed	NULL
them	NULL
to	NULL
become	NULL
activated	NULL
and	NULL
progress	NULL
from	NULL
the	NULL
GyG	NULL
phase	NULL
into	NULL
S	NULL
and	NULL
G	NULL
;	NULL
/M	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

This	NULL
reversal	NULL
of	NULL
the	NULL
IL-10	NULL
effect	NULL
by	NULL
IL-2	NULL
occurred	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
.	NULL

A	NULL
similar	NULL
experiment	NULL
was	NULL
performed	NULL
in	NULL
which	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
IL-10	NULL
for	NULL
2	NULL
days	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
IL-2	NULL
and	NULL
SEB	NULL
(	NULL
Table	NULL
7	NULL
)	NULL
.	NULL

Results	NULL
very	NULL
similar	NULL
to	NULL
those	NULL
in	NULL
Table	NULL
6	NULL
were	NULL
seen	NULL
in	NULL
which	NULL
the	NULL
addition	NULL
of	NULL
IL-2	NULL
reversed	NULL
the	NULL
Gy/G	NULL
block	NULL
imposed	NULL
by	NULL
IL-10	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
.	NULL

In	NULL
either	NULL
case	NULL
,	NULL
the	NULL
concentration	NULL
of	NULL
IL-2	NULL
required	NULL
to	NULL
Table	NULL
6	NULL
.	NULL

Flow	NULL
Cytometry	NULL
Analysis	NULL
of	NULL
the	NULL
Effect	NULL
of	NULL
IL-2	NULL
Addition	NULL
on	NULL
Reversing	NULL
the	NULL
Effect	NULL
of	NULL
IL-10	NULL
on	NULL
SEB-Stimulated	NULL
CD4+	NULL
T	NULL
Cells	NULL
:	NULL
No	NULL
IL-10	NULL
Pretreatment	NULL
Cell	NULL
Cycle	NULL
Distribution	NULL
(	NULL
%	NULL
)	NULL
*	NULL
IL-2	NULL
L_______________	NULL
(	NULL
U/m	NULL
L	NULL
}	NULL
IL-10	NULL
SEB	NULL
G	NULL
:	NULL
S	NULL
0	NULL
-	NULL
-	NULL
>	NULL
98	NULL
<	NULL
1	NULL
<	NULL
1	NULL
0	NULL
-	NULL
+	NULL
63.80	NULL
29.10	NULL
710	NULL
100	NULL
+	NULL
+	NULL
59.70	NULL
33.40	NULL
6.90	NULL
30	NULL
+	NULL
+	NULL
60.60	NULL
31.90	NULL
7.50	NULL
10	NULL
+	NULL
+	NULL
72.30	NULL
22.10	NULL
5.60	NULL
3	NULL
+	NULL
+	NULL
77.30	NULL
17.90	NULL
4.80	NULL
0	NULL
+	NULL
+	NULL
80.50	NULL
15.00	NULL
4.50	NULL
100	NULL
-	NULL
+	NULL
48.60	NULL
42.70	NULL
8.70	NULL
3	NULL
-	NULL
+	NULL
59.50	NULL
32.30	NULL
8.10	NULL
100	NULL
+	NULL
-	NULL
94.40	NULL
5.00	NULL
0.60	NULL
3	NULL
+	NULL
-	NULL
98.40	NULL
1.40	NULL
0.20	NULL
100	NULL
-	NULL
-	NULL
92.70	NULL
6.30	NULL
1.00	NULL
3	NULL
-	NULL
-	NULL
97.60	NULL
2.00	NULL
0.40	NULL
*	NULL
PBM	NULL
Cs	NULL
were	NULL
treated	NULL
simultaneously	NULL
with	NULL
IL-10	NULL
(	NULL
10	NULL
U/mL	NULL
)	NULL
,	NULL
SEB	NULL
(	NULL
100	NULL
pg/mL	NULL
)	NULL
,	NULL
and	NULL
IL-2	NULL
at	NULL
the	NULL
indicated	NULL
concentrations	NULL
for	NULL
5.5	NULL
days	NULL
before	NULL
flow	NULL
cytometry	NULL
analysis	NULL
.	NULL

Data	NULL
were	NULL
gated	NULL
to	NULL
analyze	NULL
CD4+	NULL
T	NULL
cells	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IL-10	NULL
BLOCKS	NULL
CELL	NULL
CYCLING	NULL
IN	NULL
ACTIVATED	NULL
T	NULL
CELLS	NULL
Table	NULL
7	NULL
.	NULL

Flow	NULL
Cytometry	NULL
Analysis	NULL
of	NULL
the	NULL
Effect	NULL
IL-2	NULL
Addition	NULL
on	NULL
Reversing	NULL
the	NULL
Effect	NULL
of	NULL
IL-10	NULL
on	NULL
SEB-Stimulated	NULL
CD4+	NULL
T	NULL
Cells	NULL
:	NULL
Two	NULL
Day	NULL
IL-10	NULL
Pretreatment	NULL
Cell	NULL
Cycle	NULL
Distribution	NULL
(	NULL
%	NULL
)	NULL
*	NULL
IL-2	NULL
___	NULL
(	NULL
U/mL	NULL
)	NULL
IL-10	NULL
SEB	NULL
G	NULL
;	NULL
S	NULL
Go/M	NULL
0	NULL
-	NULL
-	NULL
>	NULL
98	NULL
<	NULL
1	NULL
<	NULL
1	NULL
0	NULL
-	NULL
+	NULL
73.70	NULL
23.20	NULL
3.10	NULL
100	NULL
+	NULL
+	NULL
61.20	NULL
33.20	NULL
5.60	NULL
30	NULL
+	NULL
+	NULL
62.10	NULL
32.60	NULL
5.30	NULL
10	NULL
+	NULL
+	NULL
79.50	NULL
16.00	NULL
4.50	NULL
3	NULL
+	NULL
+	NULL
88.30	NULL
9.50	NULL
2.20	NULL
0	NULL
+	NULL
+	NULL
89.20	NULL
8.70	NULL
2.00	NULL
100	NULL
-	NULL
+	NULL
53.40	NULL
41.20	NULL
5.40	NULL
3	NULL
-	NULL
+	NULL
70.80	NULL
24.70	NULL
4.50	NULL
100	NULL
+	NULL
-	NULL
80.80	NULL
16.80	NULL
240	NULL
3	NULL
+	NULL
-	NULL
93.30	NULL
5.50	NULL
1.10	NULL
100	NULL
-	NULL
-	NULL
65.70	NULL
29.40	NULL
4.90	NULL
3	NULL
-	NULL
-	NULL
74.00	NULL
23.80	NULL
2.20	NULL
*PBMCs	NULL
were	NULL
treated	NULL
for	NULL
2	NULL
days	NULL
with	NULL
IL-10	NULL
(	NULL
10	NULL
U/mL	NULL
)	NULL
.	NULL

They	NULL
were	NULL
then	NULL
incubated	NULL
with	NULL
SEB	NULL
(	NULL
100	NULL
pg/mL	NULL
)	NULL
and	NULL
IL-2	NULL
at	NULL
the	NULL
indicated	NULL
concentrations	NULL
for	NULL
5.5	NULL
days	NULL
before	NULL
flow	NULL
cytometry	NULL
analysis	NULL
.	NULL

Data	NULL
were	NULL
gated	NULL
to	NULL
analyze	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

produce	NULL
an	NULL
approximately	NULL
50	NULL
%	NULL
reversal	NULL
of	NULL
inhibition	NULL
was	NULL
similar	NULL
to	NULL
the	NULL
concentration	NULL
of	NULL
IL-2	NULL
induced	NULL
in	NULL
cultures	NULL
stimulated	NULL
by	NULL
SEB	NULL
alone	NULL
(	NULL
see	NULL
Table	NULL
4	NULL
)	NULL
.	NULL

These	NULL
IL-2	NULL
levels	NULL
probably	NULL
represent	NULL
steady-state	NULL
levels	NULL
of	NULL
IL-2	NULL
in	NULL
culture	NULL
supernatants	NULL
.	NULL

These	NULL
data	NULL
strongly	NULL
support	NULL
the	NULL
conclusion	NULL
that	NULL
one	NULL
important	NULL
mechanism	NULL
by	NULL
which	NULL
IL-10	NULL
exerts	NULL
its	NULL
effects	NULL
is	NULL
by	NULL
downregulat-ing	NULL
the	NULL
production	NULL
of	NULL
IL-2	NULL
,	NULL
especially	NULL
since	NULL
pretreatment	NULL
with	NULL
IL-10	NULL
had	NULL
no	NULL
greater	NULL
effect	NULL
on	NULL
the	NULL
ability	NULL
of	NULL
IL-2	NULL
to	NULL
reverse	NULL
the	NULL
cell	NULL
cycle	NULL
block	NULL
.	NULL

In	NULL
a	NULL
few	NULL
donors	NULL
tested	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Table	NULL
7	NULL
,	NULL
IL-10	NULL
also	NULL
inhibited	NULL
cell	NULL
cycle	NULL
progression	NULL
in	NULL
cells	NULL
stimulated	NULL
with	NULL
exogenous	NULL
IL-2	NULL
,	NULL
indicating	NULL
that	NULL
IL-10	NULL
may	NULL
also	NULL
interfere	NULL
with	NULL
the	NULL
response	NULL
of	NULL
€CD4*	NULL
T	NULL
cells	NULL
to	NULL
IL-2	NULL
to	NULL
varying	NULL
extents	NULL
.	NULL

A	NULL
Fig	NULL
3	NULL
.	NULL

Addition	NULL
of	NULL
IL-2reversestheeffectsofIL-10	NULL
_	NULL
IL-10	NULL
;	NULL
+	NULL
on	NULL
the	NULL
SEB	NULL
reduction	NULL
of	NULL
p27	NULL
``	NULL
and	NULL
SEB-induced	NULL
SEB	NULL
;	NULL
+	NULL
upregulation	NULL
of	NULL
cyclin	NULL
D2	NULL
in	NULL
CD4+	NULL
T	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
PBMCs	NULL
IL-2	NULL
;	NULL
213	NULL
The	NULL
addition	NULL
of	NULL
IL-2	NULL
partially	NULL
reversed	NULL
IL-10	NULL
's	NULL
effects	NULL
on	NULL
cell	NULL
cycle	NULL
proteins	NULL
p27	NULL
``	NULL
and	NULL
cyclin	NULL
D2	NULL
in	NULL
SEB-stimulated	NULL
CD4+	NULL
T	NULL
cells	NULL
.	NULL

-	NULL
We	NULL
next	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
adding	NULL
exogenous	NULL
IL-2	NULL
on	NULL
the	NULL
levels	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
proteins	NULL
p27	NULL
``	NULL
``	NULL
and	NULL
cyclin	NULL
D2	NULL
in	NULL
CD4+*	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
concentrated	NULL
on	NULL
p27	NULL
``	NULL
and	NULL
cyclin	NULL
D2	NULL
,	NULL
because	NULL
changes	NULL
in	NULL
p27	NULL
``	NULL
and	NULL
cyclin	NULL
D2	NULL
occur	NULL
earlier	NULL
in	NULL
G	NULL
as	NULL
compared	NULL
with	NULL
cyclin	NULL
D3	NULL
.	NULL

PBMCs	NULL
were	NULL
treated	NULL
simultaneously	NULL
with	NULL
IL-10	NULL
,	NULL
SEB	NULL
,	NULL
and	NULL
IL-2	NULL
.	NULL

The	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
then	NULL
isolated	NULL
and	NULL
the	NULL
cell	NULL
extracts	NULL
were	NULL
subjected	NULL
to	NULL
Western	NULL
analysis	NULL
as	NULL
described	NULL
before	NULL
.	NULL

As	NULL
seen	NULL
in	NULL
Fig	NULL
3	NULL
,	NULL
p27	NULL
``	NULL
levels	NULL
again	NULL
decreased	NULL
in	NULL
SEB-treated	NULL
cultures	NULL
by	NULL
day	NULL
3.5	NULL
and	NULL
remained	NULL
high	NULL
in	NULL
cultures	NULL
treated	NULL
with	NULL
IL-10	NULL
,	NULL
as	NULL
described	NULL
earlier	NULL
(	NULL
see	NULL
Fig	NULL
2	NULL
)	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
IL-2	NULL
along	NULL
with	NULL
the	NULL
IL-10	NULL
and	NULL
SEB	NULL
caused	NULL
the	NULL
p27©®	NULL
``	NULL
levels	NULL
to	NULL
decrease	NULL
to	NULL
nearly	NULL
those	NULL
seen	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
SEB	NULL
only	NULL
.	NULL

Figure	NULL
3	NULL
also	NULL
shows	NULL
the	NULL
effects	NULL
of	NULL
adding	NULL
IL-2	NULL
on	NULL
the	NULL
level	NULL
of	NULL
cyclins	NULL
D2	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
IL-2	NULL
to	NULL
cells	NULL
treated	NULL
with	NULL
SEB	NULL
and	NULL
IL-10	NULL
significantly	NULL
restored	NULL
the	NULL
expression	NULL
of	NULL
cyclin	NULL
D2	NULL
.	NULL

These	NULL
data	NULL
thus	NULL
demonstrate	NULL
that	NULL
one	NULL
mechanism	NULL
by	NULL
which	NULL
IL-10	NULL
inhibits	NULL
entry	NULL
into	NULL
the	NULL
G	NULL
;	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
is	NULL
by	NULL
the	NULL
blockage	NULL
of	NULL
IL-2	NULL
production	NULL
that	NULL
is	NULL
critical	NULL
to	NULL
the	NULL
downregulation	NULL
of	NULL
p27	NULL
``	NULL
and	NULL
the	NULL
upregulation	NULL
of	NULL
early	NULL
D-type	NULL
cyclins	NULL
in	NULL
T-cell	NULL
activation	NULL
.	NULL

Absence	NULL
of	NULL
a	NULL
complete	NULL
block	NULL
of	NULL
p27	NULL
``	NULL
induction	NULL
and	NULL
restoration	NULL
of	NULL
the	NULL
active	NULL
form	NULL
of	NULL
cyclin	NULL
D2	NULL
,	NULL
as	NULL
per	NULL
Fig	NULL
3	NULL
,	NULL
would	NULL
suggest	NULL
other	NULL
possible	NULL
IL-2-independent	NULL
effects	NULL
of	NULL
IL-10	NULL
on	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

IL-10	NULL
reduced	NULL
the	NULL
levels	NULL
of	NULL
the	NULL
IL-2	NULL
transcriptional	NULL
regulators	NULL
c-fos	NULL
and	NULL
c-jun	NULL
in	NULL
SEB-stimulated	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
effects	NULL
of	NULL
IL-10	NULL
on	NULL
the	NULL
production	NULL
of	NULL
IL-2	NULL
at	NULL
the	NULL
molecular	NULL
level	NULL
,	NULL
we	NULL
performed	NULL
flow	NULL
cytometry	NULL
analysis	NULL
looking	NULL
specifically	NULL
at	NULL
the	NULL
transcriptional	NULL
regulatory	NULL
proteins	NULL
for	NULL
IL-2	NULL
.	NULL

AP-1	NULL
is	NULL
an	NULL
important	NULL
transcriptional	NULL
regulator	NULL
for	NULL
IL-2	NULL
and	NULL
is	NULL
a	NULL
heterodimer	NULL
composed	NULL
of	NULL
the	NULL
proteins	NULL
c-fos	NULL
and	NULL
c-jun	NULL
.	NULL
``	NULL

As	NULL
seen	NULL
in	NULL
Fig	NULL
4	NULL
,	NULL
flow	NULL
cytometry	NULL
showed	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
both	NULL
c-fos	NULL
and	NULL
c-jun	NULL
proteins	NULL
in	NULL
CD4*	NULL
T	NULL
cells	NULL
induced	NULL
by	NULL
treatment	NULL
with	NULL
SEB	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
cells	NULL
becoming	NULL
acti-	NULL
e®	NULL
®	NULL
B	NULL
o	NULL
Bo	NULL
04	NULL
®	NULL
P	NULL
e	NULL
cae	NULL
4000	NULL
0	NULL
400	NULL
ko	NULL
4	NULL
o	NULL
40	NULL
4	NULL
were	NULL
incubated	NULL
in	NULL
6-well	NULL
plates	NULL
at	NULL
6	NULL
x	NULL
10°	NULL
cells/mL	NULL
along	NULL
with	NULL
IL-10	NULL
at	NULL
10	NULL
U/mL	NULL
or	NULL
media	NULL
only	NULL
.	NULL

After	NULL
2	NULL
days	NULL
of	NULL
incubation	NULL
,	NULL
media	NULL
alone	NULL
,	NULL
SEB	NULL
at	NULL
100	NULL
pg/mL	NULL
,	NULL
or	NULL
SEB	NULL
and	NULL
IL-2	NULL
(	NULL
100	NULL
U/mL	NULL
)	NULL
were	NULL
added	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
further	NULL
incubated	NULL
until	NULL
the	NULL
indicated	NULL
harvest	NULL
day	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
and	NULL
CD4+*	NULL
T	NULL
cells	NULL
were	NULL
separated	NULL
and	NULL
collected	NULL
by	NULL
negative	NULL
selection	NULL
affinity	NULL
chromatography	NULL
.	NULL

Lysates	NULL
from	NULL
these	NULL
cells	NULL
were	NULL
subjected	NULL
to	NULL
SDS-PAGE	NULL
and	NULL
Western	NULL
analysis	NULL
using	NULL
antibodies	NULL
specific	NULL
for	NULL
p27®®	NULL
!	NULL

and	NULL
cyclin	NULL
D2	NULL
.	NULL

The	NULL
B	NULL
lower	NULL
band	NULL
in	NULL
the	NULL
cyclin	NULL
D2	NULL
doublet	NULL
represents	NULL
the	NULL
8	NULL
DAY	NULL
:	NULL
2.5	NULL
3.5	NULL
2.5	NULL
3.5	NULL
2.5	NULL
3.5	NULL
25	NULL
3.5	NULL
3.5	NULL
To	NULL
--	NULL
--	NULL
me	NULL
=	NULL
e	NULL
<	NULL
-	NULL
es	NULL
=	NULL
<	NULL
cyclin	NULL
|	NULL
)	NULL
?	NULL

faster-migrating	NULL
activated	NULL
form	NULL
of	NULL
cyclin	NULL
D2	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Quantitation	NULL
w	NULL
as	NULL
performed	NULL
by	NULL
densitometric	NULL
analysis	NULL
of	NULL
bands	NULL
from	NULL
day	NULL
3.5	NULL
.	NULL

The	NULL
differences	NULL
between	NULL
SEB	NULL
treatment	NULL
and	NULL
treatment	NULL
with	NULL
IL-10	NULL
and	NULL
SEB	NULL
were	NULL
found	NULL
to	NULL
be	NULL
statistically	NULL
significant	NULL
for	NULL
both	NULL
immunoblots	NULL
(	NULL
P	NULL
<	NULL
.001	NULL
)	NULL
by	NULL
the	NULL
Student	NULL
's	NULL
f-test	NULL
.	NULL

Differences	NULL
were	NULL
also	NULL
statistically	NULL
significant	NULL
when	NULL
comparing	NULL
IL-10	NULL
and	NULL
SEB	NULL
treatments	NULL
with	NULL
those	NULL
Fold	NULL
Decrease	NULL
in	NULL
which	NULL
IL-2	NULL
was	NULL
also	NULL
added	NULL
:	NULL
P	NULL
<	NULL
.001	NULL
for	NULL
the	NULL
p27	NULL
``	NULL
®	NULL
``	NULL
'	NULL
blot	NULL
and	NULL
P	NULL
<	NULL
.002	NULL
for	NULL
the	NULL
activated	NULL
form	NULL
in	NULL
the	NULL
cyclin	NULL
D2	NULL
.	NULL

Control	NULL
SEB	NULL
Only	NULL
IL-10	NULL
+	NULL
SEB	NULL
A	NULL
B	NULL
®	NULL
0	NULL
IL-10	NULL
+	NULL
SEB	NULL
+	NULL
IL-2	NULL
Fold	NULL
Increase	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

214	NULL
80	NULL
N	NULL
c-fos	NULL
&	NULL
g	NULL
{	NULL
cjun	NULL
£	NULL
604	NULL
A	NULL
2	NULL
w	NULL
a	NULL
Fa	NULL
a	NULL
&	NULL
40-=	NULL
<	NULL
3	NULL
ea	NULL
2	NULL
20-	NULL
&	NULL
5	NULL
&	NULL
pd	NULL
0-SEB	NULL
only	NULL
IL-10	NULL
+	NULL
SEB	NULL
Treatment	NULL
Fig	NULL
4	NULL
.	NULL

IL-10	NULL
reduces	NULL
SEB	NULL
induction	NULL
of	NULL
c-fos	NULL
and	NULL
c-jun	NULL
proteins	NULL
in	NULL
CD4+	NULL
T	NULL
cells	NULL
.	NULL

PBMCs	NULL
were	NULL
incubated	NULL
in	NULL
6-well	NULL
plates	NULL
at	NULL
6	NULL
x	NULL
10°	NULL
cells/	NULL
mL	NULL
with	NULL
media	NULL
alone	NULL
,	NULL
SEB	NULL
(	NULL
100	NULL
pg/mL	NULL
)	NULL
,	NULL
or	NULL
IL-10	NULL
(	NULL
10	NULL
U/mL	NULL
)	NULL
and	NULL
SEB	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
for	NULL
45	NULL
minutes	NULL
,	NULL
harvested	NULL
,	NULL
and	NULL
subjected	NULL
to	NULL
flow	NULL
cytometry	NULL
analysis	NULL
.	NULL

Data	NULL
were	NULL
gated	NULL
to	NULL
analyze	NULL
CD4+	NULL
T	NULL
cells	NULL
.	NULL

Results	NULL
were	NULL
determined	NULL
to	NULL
be	NULL
statistically	NULL
significant	NULL
by	NULL
the	NULL
Student	NULL
's	NULL
f-test	NULL
(	NULL
P	NULL
<	NULL
.01	NULL
for	NULL
c-fos	NULL
and	NULL
P	NULL
<	NULL
.0005	NULL
for	NULL
c-jun	NULL
)	NULL
.	NULL

These	NULL
values	NULL
represent	NULL
net	NULL
effects	NULL
after	NULL
the	NULL
subtraction	NULL
of	NULL
relative	NULL
fluorescent	NULL
intensity	NULL
for	NULL
untreated	NULL
cells	NULL
.	NULL

vated	NULL
.	NULL

We	NULL
further	NULL
show	NULL
that	NULL
the	NULL
addition	NULL
of	NULL
IL-10	NULL
to	NULL
these	NULL
cultures	NULL
along	NULL
with	NULL
SEB	NULL
caused	NULL
a	NULL
decrease	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
the	NULL
c-fos	NULL
and	NULL
c-jun	NULL
proteins	NULL
.	NULL

There	NULL
appeared	NULL
to	NULL
be	NULL
a	NULL
stronger	NULL
effect	NULL
of	NULL
IL-10	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
c-fos	NULL
than	NULL
c-jun	NULL
,	NULL
but	NULL
the	NULL
reason	NULL
for	NULL
this	NULL
is	NULL
not	NULL
known	NULL
at	NULL
this	NULL
time	NULL
.	NULL

These	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
our	NULL
data	NULL
showing	NULL
that	NULL
IL-10	NULL
can	NULL
significantly	NULL
decrease	NULL
the	NULL
amount	NULL
of	NULL
IL-2	NULL
produced	NULL
by	NULL
cells	NULL
stimulated	NULL
with	NULL
SEB	NULL
and	NULL
prevents	NULL
CD4*	NULL
T	NULL
cells	NULL
from	NULL
becoming	NULL
activated	NULL
and	NULL
entering	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

IL-10	NULL
blocks	NULL
proliferation	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
effects	NULL
of	NULL
IL-10	NULL
on	NULL
CD4*	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
antigen-presenting	NULL
cells	NULL
(	NULL
APCs	NULL
)	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
antiproliferative	NULL
effects	NULL
of	NULL
IL-10	NULL
on	NULL
CD4*	NULL
T	NULL
cells	NULL
in	NULL
a	NULL
system	NULL
depleted	NULL
of	NULL
APCs	NULL
.	NULL

CD4*	NULL
T	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
PBMCs	NULL
and	NULL
their	NULL
purity	NULL
was	NULL
verified	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

These	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
either	NULL
with	NULL
SEB	NULL
or	NULL
a	NULL
mixture	NULL
of	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
and	NULL
ionomycin	NULL
and	NULL
their	NULL
proliferation	NULL
was	NULL
measured	NULL
by	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
.	NULL

SEB	NULL
is	NULL
a	NULL
unique	NULL
superantigen	NULL
in	NULL
that	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
directly	NULL
activate	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
APCs	NULL
.	NULL
``	NULL

Figure	NULL
5A	NULL
shows	NULL
that	NULL
SEB	NULL
did	NULL
induce	NULL
CD4*	NULL
T	NULL
cells	NULL
to	NULL
proliferate	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
APCs	NULL
and	NULL
that	NULL
IL-10	NULL
was	NULL
able	NULL
to	NULL
significantly	NULL
block	NULL
this	NULL
proliferation	NULL
.	NULL

PHA	NULL
,	NULL
whose	NULL
effects	NULL
are	NULL
known	NULL
to	NULL
be	NULL
APC	NULL
dependent	NULL
,	NULL
``	NULL
had	NULL
a	NULL
negligible	NULL
effect	NULL
on	NULL
proliferation	NULL
of	NULL
the	NULL
CD4*	NULL
T-cell	NULL
population	NULL
used	NULL
while	NULL
also	NULL
stimulating	NULL
a	NULL
population	NULL
that	NULL
contained	NULL
APCs	NULL
.	NULL

We	NULL
also	NULL
stimulated	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
with	NULL
varying	NULL
mixtures	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
which	NULL
can	NULL
also	NULL
directly	NULL
activate	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

IL-10	NULL
significantly	NULL
inhibited	NULL
the	NULL
proliferation	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
at	NULL
all	NULL
of	NULL
the	NULL
PMA	NULL
concentrations	NULL
tested	NULL
(	NULL
Fig	NULL
5B	NULL
)	NULL
and	NULL
also	NULL
at	NULL
various	NULL
ionomycin	NULL
concentrations	NULL
tested	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
data	NULL
show	NULL
that	NULL
IL-10	NULL
had	NULL
a	NULL
direct	NULL
antiproliferative	NULL
effect	NULL
on	NULL
CD4+*	NULL
T	NULL
cells	NULL
and	NULL
that	NULL
these	NULL
antiproliferative	NULL
effects	NULL
are	NULL
independent	NULL
of	NULL
IL-10	NULL
's	NULL
effects	NULL
on	NULL
APCs	NULL
,	NULL
such	NULL
as	NULL
downregulation	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
and	NULL
downregulation	NULL
of	NULL
€CD80/86	NULL
PERRIN	NULL
,	NULL
JOHNSON	NULL
,	NULL
AND	NULL
SUBRAMANIAM	NULL
molecules	NULL
.	NULL

Furthermore	NULL
,	NULL
these	NULL
data	NULL
provide	NULL
functional	NULL
evidence	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
IL-10	NULL
receptors	NULL
on	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

DISCUSSION	NULL
The	NULL
immunosuppressive	NULL
effects	NULL
of	NULL
IL-10	NULL
have	NULL
been	NULL
well	NULL
documented	NULL
in	NULL
a	NULL
number	NULL
of	NULL
different	NULL
systems	NULL
both	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
.	NULL
``	NULL

However	NULL
,	NULL
the	NULL
mechanism	NULL
of	NULL
these	NULL
effects	NULL
at	NULL
the	NULL
level	NULL
of	NULL
cell	NULL
cycle	NULL
events	NULL
is	NULL
currently	NULL
not	NULL
known	NULL
.	NULL

We	NULL
showed	NULL
here	NULL
that	NULL
IL-10	NULL
blocks	NULL
SEB-stimulated	NULL
CD4*	NULL
T	NULL
cells	NULL
from	NULL
entering	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Specifically	NULL
,	NULL
IL-10	NULL
treatment	NULL
of	NULL
cells	NULL
prevented	NULL
the	NULL
downregulation	NULL
of	NULL
p27	NULL
P	NULL
'	NULL
,	NULL
a	NULL
cell	NULL
cycle	NULL
inhibitory	NULL
protein	NULL
.	NULL

Resting	NULL
cells	NULL
are	NULL
characterized	NULL
by	NULL
relatively	NULL
high	NULL
levels	NULL
of	NULL
p27	NULL
``	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
cyclin-edk	NULL
complexes	NULL
,	NULL
inhibiting	NULL
phos-	NULL
A	NULL
25000	NULL
®	NULL
xo-10	NULL
C	NULL
1L-10	NULL
(	NULL
10	NULL
Ua	NULL
)	NULL
20000	NULL
-	NULL
31.0	NULL
%	NULL
CD4+	NULL
T	NULL
cells	NULL
Only	NULL
0.1	NULL
PS	NULL
C	NULL
rem	NULL
150007	NULL
is	NULL
&	NULL
O	NULL
10000	NULL
59.0	NULL
%	NULL
sooo	NULL
-	NULL
p	NULL
<	NULL
0.001	NULL
21.3	NULL
%	NULL
p	NULL
<	NULL
0.02	NULL
o-10	NULL
ng/ml	NULL
1	NULL
ng/ml	NULL
100	NULL
pg/ml	NULL
5	NULL
ug/ml	NULL
-	NULL
3	NULL
ug/ml	NULL
SEB	NULL
PHA	NULL
50000	NULL
E	NULL
NOL-i0	NULL
CD4+	NULL
T	NULL
cells	NULL
Only	NULL
C	NULL
111000	NULL
U/im	NULL
)	NULL
|	NULL
[	NULL
J	NULL
PBMC	NULL
40000	NULL
30000	NULL
7	NULL
a	NULL
5	NULL
Bot	NULL
72.7	NULL
%	NULL
<	NULL
0.01	NULL
``	NULL
200007	NULL
P	NULL
p	NULL
<	NULL
0.001	NULL
79.6	NULL
%	NULL
p	NULL
<	NULL
0.005	NULL
10000	NULL
-a-	NULL
ng/ml	NULL
L	NULL
ng/ml	NULL
300	NULL
pg/ml	NULL
5	NULL
ug/ml	NULL
-	NULL
3ug/ml	NULL
PMA	NULL
PHA	NULL
Fig	NULL
5	NULL
.	NULL

IL-10	NULL
blocks	NULL
proliferation	NULL
of	NULL
CD4+*	NULL
T	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
CD4+*	NULL
T	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
PBMCs	NULL
by	NULL
negative	NULL
selection	NULL
chromatography	NULL
and	NULL
were	NULL
added	NULL
to	NULL
96-well	NULL
plates	NULL
at	NULL
2.5	NULL
x	NULL
10°	NULL
cells/mL	NULL
along	NULL
with	NULL
IL-10	NULL
at	NULL
10	NULL
U/mL	NULL
or	NULL
media	NULL
only	NULL
.	NULL

After	NULL
incubating	NULL
for	NULL
2	NULL
hours	NULL
,	NULL
SEB	NULL
at	NULL
varying	NULL
concentrations	NULL
was	NULL
added	NULL
and	NULL
plates	NULL
were	NULL
incubated	NULL
for	NULL
4	NULL
days	NULL
.	NULL

Proliferation	NULL
was	NULL
measured	NULL
by	NULL
incorporation	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
mean	NULL
CPM	NULL
+	NULL
SD	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
suppression	NULL
by	NULL
IL-10	NULL
and	NULL
statistical	NULL
significance	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
the	NULL
Student	NULL
's	NULL
t-test	NULL
,	NULL
for	NULL
each	NULL
treatment	NULL
are	NULL
indicated	NULL
above	NULL
the	NULL
graphs	NULL
.	NULL

(	NULL
B	NULL
)	NULL
CD4+	NULL
T	NULL
cells	NULL
were	NULL
incubated	NULL
as	NULL
indicated	NULL
above	NULL
and	NULL
stimulated	NULL
with	NULL
a	NULL
mixture	NULL
of	NULL
ionomycin	NULL
(	NULL
100	NULL
ng/mL	NULL
)	NULL
and	NULL
varying	NULL
concentrations	NULL
of	NULL
PM	NULL
A	NULL
.	NULL

Proliferation	NULL
was	NULL
measured	NULL
by	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
mean	NULL
CPM	NULL
+	NULL
SD	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
suppression	NULL
by	NULL
IL-10	NULL
and	NULL
statistical	NULL
significance	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
the	NULL
Student	NULL
's	NULL
t-test	NULL
,	NULL
for	NULL
each	NULL
treatment	NULL
are	NULL
indicated	NULL
above	NULL
the	NULL
graphs	NULL
.	NULL

In	NULL
both	NULL
(	NULL
A	NULL
)	NULL
and	NULL
(	NULL
B	NULL
)	NULL
,	NULL
the	NULL
proliferation	NULL
of	NULL
CD4+	NULL
T	NULL
cells	NULL
incubated	NULL
with	NULL
PHA	NULL
at	NULL
5	NULL
ug/mL	NULL
is	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
whole	NULL
PBMCs	NULL
incubated	NULL
with	NULL
3	NULL
pg/mL	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IL-10	NULL
BLOCKS	NULL
CELL	NULL
CYCLING	NULL
IN	NULL
ACTIVATED	NULL
T	NULL
CELLS	NULL
phorylations	NULL
that	NULL
are	NULL
required	NULL
for	NULL
moving	NULL
cells	NULL
out	NULL
of	NULL
Gy	NULL
and	NULL
through	NULL
the	NULL
G	NULL
;	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL
``	NULL

IL-10	NULL
also	NULL
prevented	NULL
upregulation	NULL
of	NULL
the	NULL
G	NULL
;	NULL
cyclins	NULL
D2	NULL
and	NULL
D3	NULL
in	NULL
SEB-stimulated	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
which	NULL
are	NULL
necessary	NULL
for	NULL
the	NULL
cells	NULL
to	NULL
enter	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Cyclin	NULL
D2	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
present	NULL
at	NULL
low	NULL
levels	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
,	NULL
whereas	NULL
cyclin	NULL
D3	NULL
is	NULL
only	NULL
detected	NULL
after	NULL
T-cell	NULL
activation	NULL
.	NULL
``	NULL

Thus	NULL
,	NULL
IL-10	NULL
blocked	NULL
downregulation	NULL
of	NULL
p27	NULL
``	NULL
and	NULL
upregulation	NULL
of	NULL
cyclins	NULL
D2	NULL
and	NULL
D3	NULL
,	NULL
which	NULL
provides	NULL
a	NULL
mechanism	NULL
for	NULL
its	NULL
inhibition	NULL
of	NULL
lymphocyte	NULL
activation	NULL
.	NULL

Related	NULL
to	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
IL-10	NULL
on	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
IL-10	NULL
blocked	NULL
SEB	NULL
induction	NULL
of	NULL
IL-2	NULL
.	NULL

It	NULL
has	NULL
previously	NULL
been	NULL
shown	NULL
that	NULL
IL-10	NULL
blocked	NULL
IL-2	NULL
induction	NULL
,	NULL
but	NULL
the	NULL
consequences	NULL
of	NULL
this	NULL
in	NULL
terms	NULL
of	NULL
cell	NULL
cycle	NULL
events	NULL
have	NULL
not	NULL
been	NULL
determined	NULL
.	NULL

Addition	NULL
of	NULL
IL-2	NULL
to	NULL
cultures	NULL
treated	NULL
with	NULL
SEB	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-10	NULL
reversed	NULL
IL-10	NULL
inhibition	NULL
of	NULL
CD4*	NULL
T-cell	NULL
cycling	NULL
.	NULL

This	NULL
correlated	NULL
with	NULL
a	NULL
downregulation	NULL
of	NULL
p27	NULL
``	NULL
and	NULL
upregulation	NULL
of	NULL
cyclin	NULL
D2	NULL
.	NULL

Furthermore	NULL
,	NULL
because	NULL
pretreatment	NULL
with	NULL
IL-10	NULL
did	NULL
not	NULL
significantly	NULL
affect	NULL
responses	NULL
to	NULL
IL-2	NULL
,	NULL
it	NULL
suggests	NULL
that	NULL
events	NULL
affecting	NULL
the	NULL
binding	NULL
of	NULL
IL-2	NULL
to	NULL
its	NULL
receptor	NULL
are	NULL
probably	NULL
not	NULL
involved	NULL
in	NULL
the	NULL
immediate	NULL
effects	NULL
of	NULL
IL-10	NULL
.	NULL

However	NULL
,	NULL
the	NULL
reversal	NULL
by	NULL
exogenous	NULL
IL-2	NULL
of	NULL
the	NULL
effects	NULL
on	NULL
the	NULL
cell	NULL
cycle	NULL
proteins	NULL
p27°®	NULL
``	NULL
and	NULL
cyclin	NULL
D2	NULL
was	NULL
not	NULL
complete	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
IL-10	NULL
acts	NULL
by	NULL
IL-2-independent	NULL
mechanisms	NULL
in	NULL
addition	NULL
to	NULL
suppressing	NULL
induction	NULL
of	NULL
IL-2	NULL
.	NULL

We	NULL
have	NULL
observed	NULL
in	NULL
some	NULL
instances	NULL
that	NULL
IL-2	NULL
alone	NULL
can	NULL
induce	NULL
a	NULL
proliferative	NULL
response	NULL
,	NULL
which	NULL
varied	NULL
between	NULL
donors	NULL
.	NULL

However	NULL
,	NULL
even	NULL
in	NULL
these	NULL
instances	NULL
the	NULL
ability	NULL
of	NULL
these	NULL
cells	NULL
to	NULL
respond	NULL
to	NULL
IL-2	NULL
can	NULL
be	NULL
suppressed	NULL
by	NULL
IL-10	NULL
.	NULL

This	NULL
would	NULL
suggest	NULL
that	NULL
IL-10	NULL
could	NULL
possibly	NULL
affect	NULL
signals	NULL
that	NULL
do	NULL
not	NULL
directly	NULL
stem	NULL
from	NULL
IL-2	NULL
but	NULL
are	NULL
nonetheless	NULL
required	NULL
in	NULL
conjunction	NULL
with	NULL
IL-2-induced	NULL
signals	NULL
in	NULL
mediating	NULL
a	NULL
mitogenic	NULL
response	NULL
.	NULL

IL-10	NULL
was	NULL
examined	NULL
for	NULL
its	NULL
effect	NULL
on	NULL
inhibiting	NULL
upregulation	NULL
of	NULL
the	NULL
AP-1	NULL
transcription	NULL
factors	NULL
c-fos	NULL
and	NULL
c-jun	NULL
.	NULL

These	NULL
proteins	NULL
are	NULL
involved	NULL
in	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
as	NULL
well	NULL
as	NULL
a	NULL
number	NULL
of	NULL
other	NULL
cytokines	NULL
involved	NULL
in	NULL
cell	NULL
growth	NULL
.	NULL
``	NULL

''	NULL
Treatment	NULL
with	NULL
IL-10	NULL
caused	NULL
a	NULL
decrease	NULL
in	NULL
the	NULL
amounts	NULL
of	NULL
both	NULL
c-fos	NULL
and	NULL
c-jun	NULL
proteins	NULL
in	NULL
SEB-stimulated	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
IL-10	NULL
on	NULL
c-fos	NULL
and	NULL
c-jun	NULL
could	NULL
contribute	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
IL-2	NULL
induction	NULL
.	NULL

Given	NULL
the	NULL
broad	NULL
gene-target	NULL
specificity	NULL
of	NULL
c-fos	NULL
and	NULL
c-jun	NULL
,	NULL
it	NULL
is	NULL
probable	NULL
that	NULL
IL-10	NULL
may	NULL
also	NULL
have	NULL
effects	NULL
that	NULL
go	NULL
beyond	NULL
the	NULL
early	NULL
blockage	NULL
of	NULL
IL-2	NULL
production	NULL
.	NULL

IL-10	NULL
receptors	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
present	NULL
on	NULL
murine	NULL
CD4*	NULL
T	NULL
cells	NULL
and	NULL
CD4+*	NULL
T-cell	NULL
clones	NULL
of	NULL
the	NULL
Ty1	NULL
subtype	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
significant	NULL
levels	NULL
of	NULL
IL-10	NULL
receptor	NULL
mRNA	NULL
have	NULL
been	NULL
detected	NULL
in	NULL
human	NULL
CD4+*	NULL
T-cell	NULL
clones	NULL
.	NULL

Consistent	NULL
with	NULL
these	NULL
data	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
IL-10	NULL
directly	NULL
affects	NULL
the	NULL
proliferation	NULL
of	NULL
purified	NULL
human	NULL
CD4+*	NULL
T	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
both	NULL
the	NULL
superantigens	NULL
such	NULL
as	NULL
SEB	NULL
and	NULL
T-cell	NULL
mitogens	NULL
such	NULL
as	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

Our	NULL
data	NULL
provide	NULL
further	NULL
functional	NULL
evidence	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
IL-10	NULL
receptors	NULL
on	NULL
human	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
IL-10	NULL
induced	NULL
an	NULL
anergic	NULL
state	NULL
in	NULL
human	NULL
CD4+	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
alloantigens	NULL
or	NULL
cross-linked	NULL
with	NULL
anti-CD3	NULL
antibodies	NULL
.	NULL
``	NULL

These	NULL
studies	NULL
involved	NULL
the	NULL
long-term	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
IL-10	NULL
in	NULL
which	NULL
the	NULL
cells	NULL
become	NULL
unresponsive	NULL
to	NULL
IL-2	NULL
.	NULL

Although	NULL
we	NULL
have	NULL
not	NULL
directly	NULL
studied	NULL
the	NULL
effect	NULL
of	NULL
long-term	NULL
treatment	NULL
with	NULL
IL-10	NULL
,	NULL
we	NULL
found	NULL
that	NULL
pretreatment	NULL
of	NULL
cells	NULL
for	NULL
up	NULL
to	NULL
2	NULL
days	NULL
with	NULL
IL-10	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
ability	NULL
of	NULL
IL-2	NULL
to	NULL
reverse	NULL
the	NULL
cell	NULL
cycle	NULL
block	NULL
.	NULL

215	NULL
Thus	NULL
,	NULL
our	NULL
data	NULL
,	NULL
along	NULL
with	NULL
those	NULL
of	NULL
others	NULL
,	NULL
``	NULL
``	NULL
would	NULL
suggest	NULL
that	NULL
the	NULL
effects	NULL
of	NULL
IL-10	NULL
are	NULL
twofold	NULL
.	NULL

Short	NULL
exposures	NULL
to	NULL
IL-10	NULL
produce	NULL
an	NULL
immediate	NULL
inhibition	NULL
of	NULL
the	NULL
activation	NULL
of	NULL
CD4*	NULL
T-cell	NULL
entry	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
that	NULL
is	NULL
IL-2	NULL
dependent	NULL
and	NULL
is	NULL
reflected	NULL
by	NULL
high	NULL
levels	NULL
of	NULL
p27	NULL
``	NULL
and	NULL
low	NULL
levels	NULL
of	NULL
cyclin	NULL
D2	NULL
.	NULL

This	NULL
phase	NULL
is	NULL
reversible	NULL
by	NULL
IL-2	NULL
.	NULL

However	NULL
,	NULL
continued	NULL
treatment	NULL
with	NULL
IL-10	NULL
apparently	NULL
produces	NULL
permanent	NULL
changes	NULL
in	NULL
these	NULL
cells	NULL
that	NULL
ultimately	NULL
makes	NULL
them	NULL
unresponsive	NULL
to	NULL
IL-2	NULL
and	NULL
renders	NULL
the	NULL
cells	NULL
anergic	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
this	NULL
shift	NULL
to	NULL
a	NULL
permanent	NULL
state	NULL
of	NULL
IL-2	NULL
unresponsiveness	NULL
remains	NULL
unclear	NULL
.	NULL

IL-10	NULL
is	NULL
produced	NULL
relatively	NULL
late	NULL
in	NULL
the	NULL
immune	NULL
response	NULL
and	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
important	NULL
in	NULL
the	NULL
shift	NULL
from	NULL
a	NULL
cell-mediated	NULL
response	NULL
to	NULL
an	NULL
antibody-mediated	NULL
response	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
IL-10	NULL
functions	NULL
in	NULL
a	NULL
paracrine	NULL
fashion	NULL
,	NULL
affecting	NULL
neighboring	NULL
cells	NULL
.	NULL

Because	NULL
IL-10	NULL
effectively	NULL
blocked	NULL
cell	NULL
cycling	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
SEB	NULL
,	NULL
our	NULL
data	NULL
suggest	NULL
that	NULL
IL-10	NULL
can	NULL
prevent	NULL
naive	NULL
CD4*	NULL
T	NULL
cells	NULL
from	NULL
being	NULL
activated	NULL
even	NULL
when	NULL
they	NULL
are	NULL
subsequently	NULL
presented	NULL
with	NULL
antigen	NULL
.	NULL

This	NULL
highlights	NULL
an	NULL
important	NULL
use	NULL
for	NULL
IL-10	NULL
as	NULL
an	NULL
immunosuppressive	NULL
drug	NULL
.	NULL

Furthermore	NULL
,	NULL
when	NULL
compared	NULL
in	NULL
this	NULL
fashion	NULL
,	NULL
immunosuppressive	NULL
drugs	NULL
such	NULL
as	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
would	NULL
be	NULL
expected	NULL
to	NULL
resemble	NULL
IL-10	NULL
in	NULL
their	NULL
effects	NULL
on	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

These	NULL
drugs	NULL
act	NULL
to	NULL
prevent	NULL
T-cell	NULL
activation	NULL
primarily	NULL
by	NULL
blocking	NULL
IL-2	NULL
synthesis*	NULL
``	NULL
and	NULL
,	NULL
thereby	NULL
,	NULL
presumably	NULL
also	NULL
preventing	NULL
the	NULL
cell	NULL
cycling	NULL
of	NULL
target	NULL
cells	NULL
in	NULL
a	NULL
manner	NULL
analogous	NULL
to	NULL
IL-10	NULL
.	NULL

This	NULL
is	NULL
in	NULL
contrast	NULL
to	NULL
drugs	NULL
such	NULL
as	NULL
rapamycin	NULL
that	NULL
act	NULL
by	NULL
blocking	NULL
signaling	NULL
after	NULL
the	NULL
binding	NULL
of	NULL
IL-2	NULL
to	NULL
its	NULL
receptor	NULL
.	NULL
``	NULL

''	NULL
Rapamycin	NULL
,	NULL
like	NULL
IL-10	NULL
,	NULL
also	NULL
prevents	NULL
the	NULL
downregulation	NULL
of	NULL
p27	NULL
``	NULL
,	NULL
but	NULL
this	NULL
effect	NULL
can	NULL
not	NULL
be	NULL
reversed	NULL
by	NULL
exogenous	NULL
IL-2	NULL
.	NULL
``	NULL

Overall	NULL
,	NULL
our	NULL
results	NULL
suggest	NULL
the	NULL
importance	NULL
of	NULL
IL-10	NULL
in	NULL
regulating	NULL
the	NULL
cell	NULL
cycle	NULL
proteins	NULL
necessary	NULL
for	NULL
stimulated	NULL
CD4+*	NULL
T	NULL
cells	NULL
to	NULL
enter	NULL
the	NULL
cell	NULL
cycle	NULL
and	NULL
implicate	NULL
IL-2	NULL
as	NULL
a	NULL
key	NULL
cytokine	NULL
that	NULL
mediates	NULL
the	NULL
early	NULL
short-term	NULL
immunosuppressive	NULL
effects	NULL
of	NULL
IL-10	NULL
on	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

However	NULL
,	NULL
failure	NULL
of	NULL
IL-2	NULL
to	NULL
completely	NULL
reverse	NULL
the	NULL
IL-10	NULL
effects	NULL
would	NULL
suggest	NULL
some	NULL
direct	NULL
effects	NULL
of	NULL
IL-10	NULL
on	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

ACKNOWLEDGMENT	NULL
The	NULL
authors	NULL
gratefully	NULL
acknowledge	NULL
Melissa	NULL
Chen	NULL
and	NULL
Neal	NULL
Benson	NULL
at	NULL
the	NULL
Flow	NULL
Cytometry	NULL
Core	NULL
Facility	NULL
,	NULL
University	NULL
of	NULL
Florida	NULL
,	NULL
for	NULL
expert	NULL
assistance	NULL
with	NULL
flow	NULL
cytometry	NULL
data	NULL
acquisition	NULL
and	NULL
analysis	NULL
.	NULL

This	NULL
manuscript	NULL
is	NULL
Florida	NULL
Agricultural	NULL
Experiment	NULL
Station	NULL
,	NULL
Journal	NULL
Series	NULL
Number	NULL
R-06558	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Fiorentino	NULL
DF	NULL
,	NULL
Bond	NULL
MW	NULL
,	NULL
Mosmann	NULL
TR	NULL
:	NULL
Two	NULL
types	NULL
of	NULL
mouse	NULL
T	NULL
helper	NULL
cell	NULL
.	NULL

IV	NULL
.	NULL

Th2	NULL
clones	NULL
secrete	NULL
a	NULL
factor	NULL
that	NULL
inhibits	NULL
cytokine	NULL
production	NULL
by	NULL
Th1	NULL
clones	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
170:2081	NULL
,	NULL
1989	NULL
2	NULL
.	NULL

Mosmann	NULL
T	NULL
:	NULL
Properties	NULL
and	NULL
functions	NULL
of	NULL
interleukin-10	NULL
.	NULL

Adv	NULL
Immunol	NULL
56:1	NULL
,	NULL
1994	NULL
3.	NULL
deWaal	NULL
Malefyt	NULL
R	NULL
,	NULL
Abrams	NULL
J	NULL
,	NULL
Bennett	NULL
B	NULL
,	NULL
Figdor	NULL
CG	NULL
,	NULL
de	NULL
Vries	NULL
JE	NULL
:	NULL
Interleukin	NULL
10	NULL
(	NULL
IL-10	NULL
)	NULL
inhibits	NULL
cytokine	NULL
synthesis	NULL
by	NULL
human	NULL
monocytes	NULL
:	NULL
An	NULL
autoregulatory	NULL
role	NULL
of	NULL
IL-10	NULL
produced	NULL
by	NULL
monocytes	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
174:1209	NULL
,	NULL
1991	NULL
4	NULL
.	NULL

Ding	NULL
L	NULL
,	NULL
Shevach	NULL
EM	NULL
:	NULL
IL-10	NULL
inhibits	NULL
mitogen-induced	NULL
T	NULL
cell	NULL
proliferation	NULL
by	NULL
selectively	NULL
inhibiting	NULL
macrophage	NULL
costimulatory	NULL
func-tion	NULL
.	NULL

J	NULL
Immunol	NULL
148:3133	NULL
,	NULL
1992	NULL
5.	NULL
deWaal	NULL
Malefyt	NULL
R	NULL
,	NULL
Yssel	NULL
H	NULL
,	NULL
de	NULL
Vries	NULL
JE	NULL
:	NULL
Direct	NULL
effects	NULL
of	NULL
IL-10	NULL
on	NULL
subsets	NULL
of	NULL
human	NULL
CD4+*	NULL
T	NULL
cell	NULL
clones	NULL
and	NULL
resting	NULL
T	NULL
cells	NULL
.	NULL

Specific	NULL
inhibition	NULL
of	NULL
IL-2	NULL
production	NULL
and	NULL
proliferation	NULL
.	NULL

J	NULL
Immunol	NULL
150:4754	NULL
,	NULL
1993	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

216	NULL
6	NULL
.	NULL

Taga	NULL
K	NULL
,	NULL
Tosato	NULL
G	NULL
:	NULL
IL-10	NULL
inhibits	NULL
human	NULL
T	NULL
cell	NULL
proliferation	NULL
and	NULL
IL-2	NULL
production	NULL
.	NULL

J	NULL
Immunol	NULL
148:1143	NULL
,	NULL
1992	NULL
7	NULL
.	NULL

Taga	NULL
K	NULL
,	NULL
Mostowski	NULL
H	NULL
,	NULL
Tosato	NULL
G	NULL
:	NULL
Human	NULL
interleukin-10	NULL
can	NULL
directly	NULL
inhibit	NULL
T-cell	NULL
growth	NULL
.	NULL

Blood	NULL
81:2964	NULL
,	NULL
1993	NULL
8	NULL
.	NULL

Liu	NULL
Y	NULL
,	NULL
Wei	NULL
SH	NULL
,	NULL
Ho	NULL
AS	NULL
,	NULL
de	NULL
Waal	NULL
Malefyt	NULL
R	NULL
,	NULL
Moore	NULL
KW	NULL
:	NULL
Expression	NULL
cloning	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
human	NULL
IL-10	NULL
receptor	NULL
.	NULL

J	NULL
Immunol	NULL
152:1821	NULL
,	NULL
1994	NULL
9	NULL
.	NULL

Weber-Nordt	NULL
RM	NULL
,	NULL
Meraz	NULL
MA	NULL
,	NULL
Schreiber	NULL
RD	NULL
:	NULL
Lipopolysaccharide-dependent	NULL
induction	NULL
of	NULL
IL-10	NULL
receptor	NULL
expression	NULL
on	NULL
murine	NULL
fibroblasts	NULL
.	NULL

J	NULL
Immunol	NULL
153:3734	NULL
,	NULL
1994	NULL
10	NULL
.	NULL

Tan	NULL
JC	NULL
,	NULL
Indelicato	NULL
SR	NULL
,	NULL
Narula	NULL
SK	NULL
,	NULL
Zavodny	NULL
PJ	NULL
,	NULL
Chou	NULL
CC	NULL
:	NULL
Characterization	NULL
of	NULL
interleukin-10	NULL
receptors	NULL
on	NULL
human	NULL
and	NULL
mouse	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
268:21053	NULL
,	NULL
1993	NULL
11	NULL
.	NULL

Sherr	NULL
CJ	NULL
,	NULL
Kato	NULL
J	NULL
,	NULL
Quelle	NULL
DE	NULL
,	NULL
Matusuoka	NULL
M	NULL
,	NULL
Roussel	NULL
MF	NULL
:	NULL
D-type	NULL
cyclins	NULL
and	NULL
their	NULL
cyclin-dependent	NULL
kinases	NULL
:	NULL
G	NULL
;	NULL
phase	NULL
integrators	NULL
of	NULL
the	NULL
mitogenic	NULL
response	NULL
.	NULL

Cold	NULL
Spring	NULL
Harb	NULL
Symp	NULL
Quant	NULL
Biol	NULL
59:11	NULL
,	NULL
1994	NULL
12	NULL
.	NULL

Roberts	NULL
JM	NULL
,	NULL
Koff	NULL
A	NULL
,	NULL
Polyak	NULL
K	NULL
,	NULL
Firpo	NULL
E	NULL
,	NULL
Collins	NULL
S	NULL
,	NULL
Ohtsubo	NULL
M	NULL
,	NULL
Massague	NULL
J	NULL
:	NULL
Cyclins	NULL
,	NULL
edks	NULL
,	NULL
and	NULL
cyclin	NULL
kinase	NULL
inhibitors	NULL
.	NULL

Cold	NULL
Spring	NULL
Harb	NULL
Symp	NULL
Quant	NULL
Biol	NULL
59:31	NULL
,	NULL
1994	NULL
13	NULL
.	NULL

Nourse	NULL
J	NULL
,	NULL
Firpo	NULL
E	NULL
,	NULL
Flanagan	NULL
WM	NULL
,	NULL
Coats	NULL
S	NULL
,	NULL
Polyak	NULL
K	NULL
,	NULL
Lee	NULL
M-H	NULL
,	NULL
Massague	NULL
J	NULL
,	NULL
Crabtree	NULL
GR	NULL
,	NULL
Roberts	NULL
JM	NULL
:	NULL
Interleukin-2-mediated	NULL
elimination	NULL
of	NULL
the	NULL
p27°P	NULL
``	NULL
cyclin-dependent	NULL
kinase	NULL
inhibitor	NULL
prevented	NULL
by	NULL
rapamycin	NULL
.	NULL

Nature	NULL
372:570	NULL
,	NULL
1994	NULL
14	NULL
.	NULL

Johnson	NULL
HM	NULL
,	NULL
Russell	NULL
JK	NULL
,	NULL
Pontzer	NULL
CH	NULL
:	NULL
Staphylococcal	NULL
enterotoxin	NULL
microbial	NULL
superantigens	NULL
.	NULL

FASEB	NULL
J	NULL
5:2706	NULL
,	NULL
1991	NULL
15	NULL
.	NULL

Carlsson	NULL
R	NULL
,	NULL
Sjorgen	NULL
HO	NULL
:	NULL
Kinetics	NULL
of	NULL
IL-2	NULL
and	NULL
interferon-y	NULL
production	NULL
,	NULL
expression	NULL
of	NULL
IL-2	NULL
receptors	NULL
,	NULL
and	NULL
cell	NULL
proliferation	NULL
in	NULL
human	NULL
mononuclear	NULL
cells	NULL
exposed	NULL
to	NULL
staphylococcal	NULL
enterotoxin	NULL
A	NULL
.	NULL

Cell	NULL
Immunol	NULL
96:175	NULL
,	NULL
1985	NULL
16	NULL
.	NULL

Johnson	NULL
HM	NULL
,	NULL
Magazine	NULL
HI	NULL
:	NULL
Potent	NULL
mitogenic	NULL
activity	NULL
of	NULL
staphylococcal	NULL
enterotoxin	NULL
A	NULL
requires	NULL
induction	NULL
of	NULL
interleukin	NULL
2	NULL
.	NULL

Int	NULL
Arch	NULL
Allergy	NULL
Appl	NULL
Immunol	NULL
87:87	NULL
,	NULL
1988	NULL
PERRIN	NULL
,	NULL
JOHNSON	NULL
,	NULL
AND	NULL
SUBRAMANIAM	NULL
17	NULL
.	NULL

Torres	NULL
BA	NULL
,	NULL
Johnson	NULL
HM	NULL
:	NULL
Identification	NULL
of	NULL
an	NULL
HIV-1	NULL
NEF	NULL
peptide	NULL
that	NULL
binds	NULL
to	NULL
HLA	NULL
class	NULL
II	NULL
antigens	NULL
.	NULL

Biochem	NULL
Biophys	NULL
Res	NULL
Commun	NULL
200:1059	NULL
,	NULL
1994	NULL
18	NULL
.	NULL

Polyak	NULL
K	NULL
,	NULL
Kato	NULL
J	NULL
,	NULL
Solomon	NULL
MJ	NULL
,	NULL
Sherr	NULL
CJ	NULL
,	NULL
Massague	NULL
J	NULL
,	NULL
Roberts	NULL
JM	NULL
,	NULL
Koff	NULL
A	NULL
:	NULL
p27	NULL
``	NULL
,	NULL
a	NULL
cyclin-cdk	NULL
inhibitor	NULL
,	NULL
links	NULL
transforming	NULL
growth	NULL
factor-B	NULL
and	NULL
contact	NULL
inhibition	NULL
to	NULL
cell	NULL
cycle	NULL
arrest	NULL
.	NULL

Genes	NULL
Dev	NULL
8:9	NULL
,	NULL
1994	NULL
19	NULL
.	NULL

Ajchenbaum	NULL
F	NULL
,	NULL
Ando	NULL
K	NULL
,	NULL
DeCaprio	NULL
JA	NULL
,	NULL
Griffin	NULL
JD	NULL
:	NULL
Independent	NULL
regulation	NULL
of	NULL
human	NULL
D-type	NULL
cyclin	NULL
gene	NULL
expression	NULL
during	NULL
G	NULL
;	NULL
phase	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
268:4113	NULL
,	NULL
1993	NULL
20	NULL
.	NULL

Modiano	NULL
JF	NULL
,	NULL
Domenico	NULL
J	NULL
,	NULL
Szepesi	NULL
A	NULL
,	NULL
Lucas	NULL
JJ	NULL
,	NULL
Gelfand	NULL
EW	NULL
:	NULL
Differential	NULL
requirements	NULL
for	NULL
interleukin-2	NULL
distinguish	NULL
the	NULL
expression	NULL
and	NULL
activity	NULL
of	NULL
the	NULL
cyclin-dependent	NULL
kinases	NULL
Cdk4	NULL
and	NULL
Cdk2	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
269:32972	NULL
,	NULL
1994	NULL
21	NULL
.	NULL

Jain	NULL
J	NULL
,	NULL
Valge-Archer	NULL
VE	NULL
,	NULL
Rao	NULL
A	NULL
:	NULL
Analysis	NULL
of	NULL
the	NULL
AP-1	NULL
sites	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

J	NULL
Immunol	NULL
148:1240	NULL
,	NULL
1992	NULL
22	NULL
.	NULL

Taub	NULL
DD	NULL
,	NULL
Rogers	NULL
TJ	NULL
:	NULL
Direct	NULL
activation	NULL
of	NULL
murine	NULL
T	NULL
cells	NULL
by	NULL
staphylococcal	NULL
enterotoxins	NULL
.	NULL

Cell	NULL
Immunol	NULL
140:267	NULL
,	NULL
1992	NULL
23	NULL
.	NULL

Kruisbeck	NULL
AM	NULL
,	NULL
Shevach	NULL
E	NULL
:	NULL
Proliferative	NULL
assays	NULL
for	NULL
T	NULL
cell	NULL
function	NULL
,	NULL
in	NULL
Coligan	NULL
JE	NULL
,	NULL
Kruisbeck	NULL
AM	NULL
,	NULL
Margulies	NULL
DM	NULL
,	NULL
Shevach	NULL
EM	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
Current	NULL
Protocols	NULL
in	NULL
Immunology	NULL
,	NULL
vol	NULL
1	NULL
.	NULL

New	NULL
York	NULL
,	NULL
NY	NULL
,	NULL
Wiley	NULL
,	NULL
1992	NULL
,	NULL
p	NULL
3.12.1	NULL
24	NULL
.	NULL

Koff	NULL
A	NULL
,	NULL
Polyak	NULL
K	NULL
:	NULL
p27°®	NULL
'	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
cyclin-dependent	NULL
kinases	NULL
,	NULL
in	NULL
Meijer	NULL
L	NULL
,	NULL
Guidet	NULL
S	NULL
,	NULL
Tung	NULL
HYL	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
Progress	NULL
in	NULL
Cell	NULL
Cycle	NULL
Research	NULL
,	NULL
vol	NULL
1	NULL
.	NULL

New	NULL
York	NULL
,	NULL
NY	NULL
,	NULL
Plenum	NULL
,	NULL
1995	NULL
,	NULL
p	NULL
141	NULL
25	NULL
.	NULL

Groux	NULL
H	NULL
,	NULL
Bigler	NULL
M	NULL
,	NULL
de	NULL
Vries	NULL
JE	NULL
,	NULL
Roncarolo	NULL
M-G	NULL
:	NULL
Interleukin-10	NULL
induces	NULL
a	NULL
long-term	NULL
antigen-specific	NULL
anergic	NULL
state	NULL
in	NULL
human	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
184:19	NULL
,	NULL
1996	NULL
26	NULL
.	NULL

Schwartz	NULL
RH	NULL
:	NULL
Models	NULL
of	NULL
T	NULL
cell	NULL
anergy	NULL
:	NULL
Is	NULL
there	NULL
a	NULL
common	NULL
molecular	NULL
mechanism	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
184:1	NULL
,	NULL
1996	NULL
27	NULL
.	NULL

Ho	NULL
S	NULL
,	NULL
Clipstone	NULL
N	NULL
,	NULL
Timmermann	NULL
L	NULL
,	NULL
Northrop	NULL
J	NULL
,	NULL
Graef	NULL
I	NULL
,	NULL
Fiorentino	NULL
D	NULL
,	NULL
Nourse	NULL
J	NULL
,	NULL
Crabtree	NULL
GR	NULL
:	NULL
The	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

Clin	NULL
Immunol	NULL
Immunopathol	NULL
80:540	NULL
,	NULL
1996	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

blO	NULL
Od®	NULL
1999	NULL
93	NULL
:	NULL
208-216	NULL
Mechanism	NULL
of	NULL
Interleukin-10	NULL
Inhibition	NULL
of	NULL
T-Helper	NULL
Cell	NULL
Activation	NULL
by	NULL
Superantigen	NULL
at	NULL
the	NULL
Level	NULL
of	NULL
the	NULL
Cell	NULL
Cycle	NULL
George	NULL
Q.	NULL
Perrin	NULL
,	NULL
Howard	NULL
M.	NULL
Johnson	NULL
and	NULL
Prem	NULL
S.	NULL
Subramaniam	NULL
4	NULL
_	NULL
5	NULL
,	NULL
'	NULL
_	NULL
>	NULL
,	NULL
#	NULL
04	NULL
;	NULL
©1004	NULL
@	NULL
207	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/93/1/208.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Immunobiology	NULL
and	NULL
Immunotherapy	NULL
(	NULL
5679	NULL
articles	NULL
)	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

